EP2351574A1 - Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue - Google Patents
Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue Download PDFInfo
- Publication number
- EP2351574A1 EP2351574A1 EP09819250A EP09819250A EP2351574A1 EP 2351574 A1 EP2351574 A1 EP 2351574A1 EP 09819250 A EP09819250 A EP 09819250A EP 09819250 A EP09819250 A EP 09819250A EP 2351574 A1 EP2351574 A1 EP 2351574A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bone junction
- tendon
- junction tissue
- ligament
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008929 regeneration Effects 0.000 title claims abstract description 118
- 238000011069 regeneration method Methods 0.000 title claims abstract description 118
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 127
- 230000000694 effects Effects 0.000 claims abstract description 87
- 230000001737 promoting effect Effects 0.000 claims abstract description 86
- 230000036961 partial effect Effects 0.000 claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 230000000295 complement effect Effects 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 283
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 283
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 51
- 239000013598 vector Substances 0.000 claims description 31
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 14
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000037816 tissue injury Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 10
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 191
- 108020004414 DNA Proteins 0.000 description 164
- 210000002435 tendon Anatomy 0.000 description 78
- 210000000988 bone and bone Anatomy 0.000 description 70
- 210000003041 ligament Anatomy 0.000 description 60
- 239000000203 mixture Substances 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000009472 formulation Methods 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- 238000002278 reconstructive surgery Methods 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 239000000243 solution Substances 0.000 description 21
- 238000001356 surgical procedure Methods 0.000 description 20
- 210000002303 tibia Anatomy 0.000 description 20
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 19
- 238000013268 sustained release Methods 0.000 description 18
- 239000012730 sustained-release form Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000000835 fiber Substances 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 101150022655 HGF gene Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 229920002988 biodegradable polymer Polymers 0.000 description 15
- 239000004621 biodegradable polymer Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003094 microcapsule Substances 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 11
- 239000007921 spray Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- -1 α-naphthyl Chemical group 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 229960000448 lactic acid Drugs 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 210000002967 posterior cruciate ligament Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 102000057308 human HGF Human genes 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 210000000426 patellar ligament Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004439 collateral ligament Anatomy 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000003791 organic solvent mixture Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001513 elbow Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 101100230977 Bos taurus HGF gene Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010065433 Ligament rupture Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100230981 Mus musculus Hgf gene Proteins 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100230982 Rattus norvegicus Hgf gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 108010045569 atelocollagen Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000001279 glycosylating effect Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003407 lower extremity of femur Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000323 shoulder joint Anatomy 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- DICULBYFSUXYAH-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCO DICULBYFSUXYAH-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101100018370 Arabidopsis thaliana ICR4 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 238000012696 Interfacial polycondensation Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000007534 Patellar Dislocation Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101150027249 RL1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 108700023471 alginate-polylysine-alginate Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004223 ankle lateral ligament Anatomy 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- UUVBYOGFRMMMQL-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca].OP(O)(O)=O UUVBYOGFRMMMQL-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 235000021174 kaiseki Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108010050934 polyleucine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 108010087948 polymethionine Proteins 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000000513 rotator cuff Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- ACL anterior cruciate ligament
- PCL posterior cruciate ligament
- ACL reconstructive surgery is utilized to repair or replace injured ligaments.
- ACL reconstructive surgery in which a damaged ACL is reconstructed by replacing it with a ligament graft, the patellar tendon with bone blocks is conventionally utilized as a graft.
- Such ACL reconstructive surgery allows rehabilitation to start early because the patellar tendon can function as a ligament when the bones attach to each other.
- the surgery also has disadvantages such as postoperative pain and muscle weakness.
- ACL reconstructive surgery that utilizes as a tendon graft, a hamstring tendon (knee flexor tendon, semitendinosus tendon, gracilis tendon), which is one of the muscle tendons used in bending the knees has been reported (for example, see Non Patent Literature 1). More specifically, the surgery includes the steps of forming a bone tunnel (hole) in the upper end of the tibia and the lower end of the femur, placing one end of the tendon graft in the femur side of the bone tunnel, and placing the other end of the tendon graft in the tibia side of the bone tunnel.
- a bone tunnel hole
- the tendon graft runs between the femur and the tibia, and thereby functions.
- the tendon graft performs substantially the same function as the original ACL, thereby allowing the recovery of normal function in the knee joints.
- ACL reconstructive surgery since the object of ACL reconstructive surgery is to reconstruct the normal ACL function and the kinematics of the knee joints, it is necessary to reconstruct the tendon-bone joint tissue in the part where the tendon graft comes in contact with the bone surface in the bone tunnel with enough strength. For this reason, ACL reconstructive surgery has a disadvantage such that a long period of time is required before the tendon graft can function as a ligament.
- BMP-2 Bone Morphogenetic Protein-2: Non-Patent Literature 2
- TGF-B1 Transforming Growth Factor-B 1: Non-Patent Literature 3
- HGF Hepatocyte Growth Factor, hereinafter referred to as "HGF protein”
- HGF protein Hepatocyte Growth Factor
- tendon-bone junction tissue has a structure different from the tendon itself, and is a complicated tissue to adhere (fixate or fuse) a bone and a tendon, which are completely different from each other histologically.
- Non-Patent Literature 6 does not disclose or suggest the regeneration of such complicated tendon-bone junction tissue.
- HGF protein is reported to inhibit the expression of TGF- ⁇ 1, which, as mentioned previously, is known as a drug that promotes the regeneration of tendon-bone junction tissue (Non Patent Literature 7).
- An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. Particularly, an object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue at a contact site between a bone and a tendon or ligament graft after ACL reconstructive surgery etc., or in a space between a bone and a tendon or ligament graft after ACL reconstructive surgery etc.
- HGF protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and accomplished the invention.
- the present invention relates to a promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- an example of protein (1-e) includes "a protein that has an amino acid sequence at least 85% homologous to an amino acid sequence represented by SEQ ID NO: 3 or 4, and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue".
- the present invention relates to a use of HGF protein, or DNA encoding HGF protein.
- the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention can enhance the regeneration of the tendon-bone junction tissue or the ligament-bone junction tissue at a site in which a bone is in contact with a ligament or tendon graft separated from the bone, or in a space between the bone and the ligament or tendon graft.
- the present invention can promote adhesion (fixation or fusion) between a bone and a tendon or ligament that is separated from the bone by injury, rupture, etc.
- the present invention can enhance the regeneration of tendon-bone junction tissue or ligament-bone junction tissue in ligament reconstructive surgery of limb joints (e.g., knee, ankle, elbow, and shoulder) including ACL reconstructive surgery, PCL reconstructive surgery, collateral ligament reconstructive surgery, MPFL (medial patellofemoral ligament) reconstructive surgery, ankle lateral ligament reconstructive surgery, ulnar ligament reconstructive surgery, and tendon repair surgery etc.
- ACL reconstructive surgery e.g., knee, ankle, elbow, and shoulder
- MPFL medial patellofemoral ligament
- HGF protein has been identified as a potent mitogen for adult hepatocytes, and is called “Hepatocyte Growth Factor” (see, for example, Non-patent Literatures 4 and 5).
- Hepatocyte Growth Factor it is referred to as SF (scatter factor), TCF (Tumor Cytotoxic Factor), etc.
- HGF protein as used herein is a known substance, and can be prepared by any method as long as it is purified enough to be used as a medicament.
- HGF protein can be obtained by culturing primary cultured cells or cell lines capable of producing HGF protein, followed by separation of the HGF protein from culture supernatant etc., and purification.
- the protein can be obtained by genetic engineering techniques, for example, by inserting the gene encoding HGF protein into an appropriate vector, introducing the vector into an appropriate host cell to be transformed, and isolating a desired recombinant HGF protein from the culture supernatant of the transformant, etc. (see, for example, Japanese Unexamined Patent Publication No. H5-111382 , and Biochem. Biophys. Res. Commun., 1989, Vol. 163, p. 967 ).
- the above-mentioned host cell is not particularly limited and includes various host cells conventionally used in genetic engineering techniques, for example, Escherichia coli, yeast, animal cells, and the like.
- HGF protein is a protein obtained from a gene encoding human-derived HGF (hHGF).
- hHGF human-derived HGF
- Preferable examples of the gene encoding hHGF include DNA having the base sequence represented by SEQ ID NO: 1 or 2.
- HGF protein examples include, according to recombinant DNA techniques, the HGF protein represented by SEQ ID NO: 3 or 5 produced by a cell into which DNA having the base sequence represented by SEQ ID NO: 1 has been introduced, and the HGF protein represented by SEQ ID NO: 4 or 6 produced by a cell into which DNA having the base sequence represented by SEQ ID NO: 2 has been introduced.
- the HGF protein represented by SEQ ID NOs. 3 to 6 is a native HGF protein of human origin having mitogen activity and motogen activity as HGF. Such HGF protein is registered, for example, as Accession No. P14210 (SEQ ID NO: 3) or Accession No. NP_001010932 (SEQ ID NO: 4) in the NCBI database (NCBI-GenBank Flat File Release 164.0), or the like.
- HGF protein having the amino acid sequence represented by SEQ ID NO: 4 is a five amino acid-deleted HGF protein, in which five amino acid residues, i.e., from the 161 st to the 165 th residues in the amino acid sequence represented by SEQ ID NO: 3 are deleted.
- the aforementioned native HGF protein is glycoprotein.
- the HGF protein represented by Accession No. NP_001010932 SEQ ID NO: 4
- a sugar chain is added to Asn 289, Asn 397, Thr 471, Asn 561, and Asn 648.
- the amino acid sequence represented by SEQ ID NO: 5 or 6 is an amino acid sequence of an adult protein obtained by cleaving the 1 st to 31 st amino acid region (signal sequence) from the N terminus in the amino acid sequence represented by SEQ ID NO: 3 or 4.
- one or more means, for example, 2 to 35 amino acids, preferably 2 to 20 amino acids, and more preferably 2 to 10 amino acids; the same shall apply hereinafter
- amino acids in the amino acid sequence represented by SEQ ID NO: 3 or 4 may be deleted, substituted, inserted, or added, and similarly, its sugar chain may be deleted, substituted, inserted, or added.
- Such HGF protein can be produced by known technical methods such as genetic engineering techniques, site specific mutagenesis, etc.
- An amino acid to be inserted, substituted, or added may be an unnatural amino acid other than 20 kinds of natural amino acids.
- the unnatural amino acid may be any compound as long as it has an amino group and a carboxyl group, and for example, ⁇ -amino butyric acid etc., is included.
- the HGF protein having the amino acid sequence represented by SEQ ID NO: 4 is, as described above, a five amino acid-deleted type HGF protein, in which five amino acid residues in the amino acid sequence represented by SEQ ID NO: 3 are deleted.
- the HGF protein used in the present invention may have an amino acid sequence at least 85% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 provided that the protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- HGF protein having an amino acid sequence at least 90% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 is preferred, and HGF protein having an amino acid sequence at least 95% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 is more preferred.
- amino acid sequence represented by SEQ ID NO: 5 is 95.7% and 96.4% homologous to the amino acid sequence represented by SEQ ID NO: 3 and 4, respectively; and the amino acid sequence represented by SEQ ID NO: 6 is 95.1% and 95.7% homologous to the amino acid sequence represented by SEQ ID NO: 3 and 4, respectively.
- homologous to indicates the degree of identity between the amino acid residues that form each of the sequences when the primary structures (amino acid sequences) of the proteins are compared.
- HGF protein having an amino acid sequence that is highly homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 include human-derived HGF registered as Accession No. BAA14348 or AAC71655 in the NCBI database.
- the signal sequence comprising the 1 st to 31 st amino acid region in the amino acid sequence represented by SEQ ID NO: 3 or 4 may be replaced with a signal sequence of another protein.
- the signal sequence include a signal sequence of human serum albumin, interferon, human amylase, etc.
- the HGF protein used in the present invention may be a protein produced by a cell having DNA that hybridizes with DNA comprising a base sequence complementary to the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition.
- the stringent condition is as follows. Hybridization is carried out at about 65°C in the presence of about 0.7 to 1.0 M sodium chloride, and then washing is conducted at about 65°C in SSC solution at about a 0.1- to 2-fold concentration (a one fold concentration of SSC solution consists of 150 mM sodium chloride and 15 mM sodium citrate).
- An example of a method for producing the HGF protein of the present invention using a cell that comprises a gene coding the HGF protein, for example DNA having the base sequence represented by SEQ ID NO: 1 or 2, or DNA that hybridizes with DNA having a base sequence complementary to the aforementioned DNA under a stringent condition is a method in which primary cultured cells or cell lines having the aforementioned DNA are cultured, followed by separation of a desired HGF protein from the culture supernatant etc., and purification.
- the protein can be obtained by genetic engineering techniques, for example, by inserting the aforementioned DNA into an appropriate vector, introducing the vector into an appropriate host cell to be transformed, and isolating a desired HGF protein (recombinant protein) from the culture supernatant of the transformant (see, for example, Japanese Unexamined Patent Publication No. H5-111382 , Japanese Unexamined Patent Publication No. H11-1499 , and Biochem. Biophys. Res. Commun., 1989, Vol. 163, p. 967 ).
- HGF protein recombinant protein
- the aforementioned host cell is not particularly limited and various host cells conventionally used in genetic engineering techniques, for example, Escherichia coli, yeast, animal cells, and the like can be used. Since native HGF protein is a glycoprotein, it is preferred to use an animal cell as a host cell to produce glycoprotein as in the case of using a cell. Examples of the animal cell include CHO cells, COS cells, mouse L cells, mouse C127 cells, mouse FM3A2 cells, and the like.
- the expression vector is introduced into an animal cell by transfection methods, microinjection methods, etc. Of these, the most commonly used method is a phosphoric-acid calcium method.
- the animal cell that is transformed by transfection floating cultivation, or adhesion cultivation can be used in accordance with an ordinary method.
- MEM, RPMI 1640, and the like are commonly used.
- the HGF protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated as follows. For example, at least a bone and a tendon or ligament separated from the bone are kept immobilized using a ligament fastener etc. The target HGF protein is then reacted according to the method described in the Example below. Compared to the case where nothing is reacted (control), if effective regeneration of tendon-bone junction tissue or ligament-bone junction tissue is observed when the HGF protein is reacted, the HGF protein is considered to have an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- the presence or absence of glycosylation, and the number of glycosylation sites are not particularly limited as long as the HGF protein used in the present invention has an effect of enhancing bone elongation.
- the HGF protein may be protein in which naturally occurring sugar chains (one or more) are deleted, substituted, inserted or added.
- HGF protein in which a sugar chain is deleted, substituted, inserted, or added examples include HGF protein in which a sugar chain attached to native HGF protein has been deleted by treatment with an enzyme or the like, HGF protein in which the amino acid sequence at the glycosylation site has been mutated so as to prevent glycosylation, or HGF protein in which the amino acid sequence has been mutated so that glycosylation occurs at any other site than the naturally-occurring glycosylation site.
- HGF protein that is designed to prevent glycosylation by replacing Asn289, Asn397, Thr471, Asn561, and Asn648 with Gln289, Gln397, Gly471, Gln561, and Gln648, respectively in human HGF protein registered as Accession No. NP_001010932 in the NCBI database (NCBI-GenBank Flat File Release 164.0) ( Fukuta, K. et al., Biochemical Journal, 2005, Vol. 388, pp. 555-562 ).
- the HGF protein used in the present invention has any one of a carboxyl group (-COOH), a carboxylate (-COOM (M represents a metal)), an amide (-CONH 2 ), or an ester (-COOR) in the C-terminus.
- R in the ester may be a C 1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; a C 3-8 cycloalkyl group such as cyclopentyl and cyclohexyl; a C 6-12 aryl group such as phenyl and ⁇ -naphthyl; a C 7-14 aralkyl group such as a phenyl-(C 1-2 alkyl) group including benzyl and phenethyl, and an ⁇ -naphthyl-(C 1-2 alkyl) group including ⁇ -naphthylmethyl; a C 2-6 alkanoylmethyl group such as acetyloxymethyl and pivaloyloxymethyl; etc.
- a C 1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, and n-buty
- the carboxyl group or carboxylate may be amidated or esterified.
- HGF protein is also included in the HGF protein used in the present invention.
- examples of the ester include the above-mentioned examples of the ester in the C-terminus.
- the HGF protein used in the present invention includes the above-mentioned protein having an amino group of the N-terminal methionine residue protected with a protecting group (for example, a C 1-6 acyl group including a formyl group and a C 2-6 alkanoyl group such as acetyl, etc.), the above-mentioned protein having a glutamyl group pyroglutamated after being produced by cleaving the N-terminal side in vivo, the above-mentioned protein having a side chain reactive group of the amino acid in a molecule (for example, -OH, -SH, an amino group, an imidazolyl group, an indolyl group, a guanidino group, etc.) protected with an appropriate protecting group (for example, a C 1-6 acyl group including a formyl group and a C 2-6 alkanoyl group (e.g., acetyl), etc.), and a complex protein such as a glyco
- HGF protein used in the present invention the above-mentioned protein of human origin is suitably used for human application.
- HGF protein derived from mammals other than humans such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, and chimpanzees, may be used.
- HGF protein includes, but is not limited to, HGF protein registered in the NCBI database, for example, mouse HGF protein (for example, registered as Accession No. AAB31855, NP_034557, BAA01065, BAA01064, or the like), rat HGF protein (for example, registered as Accession No. NP_058713, bovine HGF protein (for example, registered as Accession No. NP_001026921, BAD02475, or the like), feline HGF protein (for example, registered as Accession No. NP_001009830, BAC10545, BAB21499, or the like), canine HGF protein (for example, registered as Accession No. NP_001002964, BAC57560, or the like), chimpanzee HGF protein (for example, registered as Accession No. XP 519174 or the like), etc.
- mouse HGF protein for example, registered as Accession No. AAB31855, NP_034557, BAA01065, BAA0106
- the HGF protein when used as the active ingredient of the promoter of the present invention, the HGF protein can be produced by any methods as long as it is purified enough to be used as a medicament.
- the purification methods are not limited, and examples thereof include column chromatography using heparin sepharose, hydroxyapatite, etc.
- HGF protein may be used alone, or as a mixed protein with various proteins as long as the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue is not impaired.
- the partial peptide of HGF protein used in the present invention (sometimes hereinafter abbreviated as HGF partial peptide), the peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue is not limited as long as it is a partial peptide of the aforementioned HGF protein and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the aforementioned HGF protein.
- the HGF partial peptide has an amino acid sequence that constitutes the above-mentioned HGF protein and comprises about 20 amino acids or more, preferably about 50 amino acids or more, and more preferably about 100 amino acids or more.
- examples of such an HGF partial peptide include a peptide having an amino acid sequence between the 32 nd and the 210 th residues from the N-terminus in the human HGF amino acid sequence represented by SEQ ID NO: 3 (an amino acid sequence from the N-terminal hairpin loop to the 1 st kringle domain of HGF), a peptide having the amino acid sequence between the 32 nd and the 288 th residues from the N-terminus in the human HGF amino acid sequence represented by SEQ ID NO: 3 (an amino acid sequence from the N-terminal hairpin loop to the 2 nd kringle domain of HGF), and the like.
- HGF partial peptide of the present invention examples include a partial peptide having an amino acid sequence at least about 80%, preferably at least about 90%, and more preferably at least about 95% homologous to the amino acid sequence of the aforementioned HGF partial peptide, and having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- the HGF partial peptide of the present invention has any one of a carboxyl group (-COOH), a carboxylate (-COOM (M is the same as defined above)), an amide (-CONH 2 ), or an ester (-COOR (R is the same as defined above)) in the C-terminus.
- the HGF partial peptide includes a peptide having an amino group of the N-terminal methionine residue protected with a protecting group, a peptide having a glutamyl group pyroglutamated after being produced by cleaving the N-terminal side in vivo , a peptide having a side chain substituent group of the amino acid within a molecule protected with an appropriate protecting group, and a complex protein such as a glycoprotein, which is produced by glycosylating the above-mentioned peptide.
- HGF partial peptide "an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above.
- the HGF partial peptide of the present invention can be prepared by known peptide synthesis methods or by cleaving HGF protein with an appropriate peptidase.
- a peptide synthesis method may be, for example, a solid- or liquid-phase synthesis method.
- the desired peptide can be prepared by condensing a partial peptide or an amino acid that is capable of constituting HGF protein and optionally having a protecting group with a remaining part optionally having a protecting group; and then by removing the protecting group, if any, from the product.
- Known condensation or protecting group removal methods include those described in, for example, M. Bodanszky and M. A.
- HGF partial peptide can be separated and purified by a combination of ordinal purification methods such as solvent extraction, distillation, column chromatography, liquid chromatography, crystallization, or recrystallization.
- the HGF protein or its partial peptide of the present invention may be in a free form (loose body), or the form of a salt.
- the salt of HGF protein or its partial peptide used in the present invention include salts that are physiologically acceptable with an acid or base. Particularly, physiologically acceptable acid adduct salts are preferred.
- salts include salts with inorganic acid (such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, and the like) and salts with organic acid (such as acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, and the like).
- inorganic acid such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, and the like
- organic acid such as acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, and the like.
- the HGF protein or the HGF partial peptide of the present invention when used in a free form, it can be converted into an appropriate salt by a known method. Meanwhile, when the HGF protein or HGF partial peptide is obtained in the form of a salt, it can be converted into a free form by a known method.
- DNA encoding HGF protein refers to DNA capable of expressing the HGF protein.
- DNA that contains DNA encoding HGF protein include DNA encoding human-derived HGF protein described in, for example, Nature, Vol. 342, p. 440 (1989 ); Japanese Patent No. 2777678 ; Biochem. Biophys. Res. Commun., 1989, Vol. 163, pp. 967-973 ; and Proc. Natl. Acad. Sci. U.S.A., 1991, Vol. 88(16), pp. 7001-7005 , and registered as Accession No. M69718, M73240, AC004960, AY246560, M29145, M73240, or the like in GenBank/EMBL/DDBJ.
- DNA encoding HGF protein used in the present invention the above-mentioned DNA of human origin is suitably used for human application.
- DNA encoding HGF protein derived from mammals other than humans such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, and chimpanzees may be used.
- DNA encoding HGF protein includes, but is not limited to, those registered in the NCBI database, for example, DNA encoding mouse HGF protein (for example, registered as Accession Nos. S71816, M_010427, D10213, D10212, or the like), DNA encoding rat HGF protein (for example, registered as Accession No. NM_017017 or the like), DNA encoding bovine HGF protein (for example, registered as Accession Nos. NM_001031751, AB110822, or the like), DNA encoding feline HGF protein (for example, registered as Accession Nos.
- NM_001009830 DNA encoding canine HGF protein (for example, registered as Accession Nos. NM_001002964, AB090353, or the like), and DNA encoding chimpanzee HGF protein (for example, registered as Accession No. XM_519174 or the like).
- DNA encoding HGF protein examples include DNA having the base sequence represented by SEQ ID NO: 1 or 2.
- the base sequence represented by SEQ ID NO: 1 corresponds to the region from the 73 rd to the 2259 th of the base sequence registered as Accession No. M60718, and also corresponds to DNA encoding HGF protein having the amino acid sequence represented by SEQ ID NO: 3.
- the HGF protein (SEQ ID NO: 3) that is expressed and produced in a cell is converted into adult HGF protein having the amino acid sequence represented by SEQ ID NO: 5 because the signal sequence is cleaved when the HGF protein is secreted outside the cell.
- DNA having the base sequence represented by SEQ ID NO: 1 corresponds to DNA encoding (producing) HGF protein having the amino acid sequence represented by SEQ ID NO: 5.
- the base sequence represented by SEQ ID NO: 2 corresponds to the region from the 66 th to the 2237 th of the base sequence registered as Accession No. M73240, and corresponds to DNA encoding HGF protein comprising the amino acid sequence represented by SEQ ID NO: 4.
- the HGF protein (SEQ ID NO: 4) is converted into adult HGF protein having the amino acid sequence represented by SEQ ID NO: 6 because the signal sequence is cleaved when the HGF protein is secreted outside the cell.
- DNA having the base sequence represented by SEQ ID NO: 2 corresponds to DNA encoding (producing) HGF protein having the amino acid sequence represented by SEQ ID NO: 6.
- DNA encoding HGF protein is not limited to the aforementioned DNA, and any DNA encoding protein having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be used as the DNA encoding HGF protein of the present invention.
- the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated in the same manner as described above.
- Such DNA is not particularly limited, but examples include DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF protein, and encodes a protein having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- the DNA encoding HGF protein can be easily obtained by a general hybridization method or PCR method using a cDNA library containing the DNA. Specifically, the DNA can be obtained with reference to Molecular Cloning, A laboratory Manual, Third Edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 2001 ; hereinafter abbreviated as Third Edition Molecular Cloning) and other basic manuals.
- Examples of the cDNA library comprising HGF protein-encoding DNA include a human liver cDNA library, a human spleen cDNA library, a human placentas cDNA library, and the like. These libraries can be commercially available from Clonetech, Co., Ltd. or the like. Other than the above, cDNA libraries produced in compliance with a known method by cell strains or tissue materials that express HGF protein can be used. According to the method described in "Third Edition Molecular Cloning", a ⁇ phage in which such cDNA has been incorporated infects Escherichia coli for culture.
- the plaque formed is then subjected to plaque hybridization or PCR using, as a probe, an oligonucleotide that is produced by a base sequence based on the partial amino acid sequence of HGF protein, thereby yielding a desired DNA encoding HGF protein.
- RNA encoding HGF protein can also be used as long as the HGF protein can be expressed by reverse transcriptase.
- examples of the RNA include RNA obtained by RT-PCR amplification of mRNA fractions harvested from cells or tissues, which is within the scope of the present invention.
- the RNA also can be obtained by known methods.
- the DNA encoding HGF protein is administered to a patient in the form of a recombinant expression vector in which DNA is inserted.
- the expression vector include, but are not limited to, naked plasmids, and DNA or RNA viruses such as detoxified retroviruses, adenoviruses, adeno-associated viruses, herpes viruses (herpes simplex virus type 1, etc.), vaccinia viruses, poxviruses, polioviruses, Sindbis viruses, Sendai viruses, SV40, and human immunodeficiency viruses (HIV).
- herpes simplex virus type 1 HSV-1
- Sendai virus envelope HVJ-E
- AAV adeno-associated virus
- the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may contain DNA coding protein that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the HGF protein, and hybridizing with DNA comprising a base sequence complementary to the DNA encoding HGF protein under a stringent condition.
- DNA coding protein that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue
- effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated in the same manner as described above.
- the DNA that hybridizes under a stringent condition with DNA comprising a base sequence complementary to the DNA encoding HGF protein, or with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 indicates DNA obtained by using a partial sequence of DNA comprising a base sequence complementary to the DNA encoding HGF protein, or with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 as a probe, and then carrying out colony hybridization, plaque hybridization, or southern blot hybridization. Specifically, DNA identified by the following procedures is included.
- a filter on which colony- or plaque-derived DNA has been immobilized is subjected to, using the probe, hybridization at about 65°C in the presence of about 0. 7 to 1.0M sodium chloride, and then the filter is washed at about 65°C in SSC solution at about 0.1- to 2-fold concentration (a one fold concentration of SSC solution consists of 150 mM sodium chloride and 15 mM sodium citrate).
- the stringent condition will be the same hereinafter.
- DNA that hybridizes under such a stringent condition includes DNA having a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF protein. More specifically, DNA that hybridizes with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition includes DNA having a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence represented by SEQ ID NO: 1 or 2.
- Hybridization can be performed according to known methods, for example the method described in Molecular Cloning, Third Edition. When a commercially available library is used, hybridization also can be performed in compliance with the method described in the attached instruction manual.
- the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may include DNA encoding HGF partial peptide that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated in the same manner as described above.
- the DNA is not limited as long as it encodes a peptide that has a base sequence encoding the partial peptide and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- examples of the DNA include DNA that has a partial base sequence of DNA having the base sequence represented by SEQ ID NO: 1 or 2, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the HGF protein.
- Preferred examples of the DNA include DNA having the region from the 94 th to the 630 th of the human HGF base sequence represented by SEQ ID NO: 1 (DNA encoding a peptide from the N-terminal hairpin loop to the 1 st kringle domain of HGF protein), and DNA having the region from the 94 th to the 864 th of the human HGF base sequence represented by SEQ ID NO: 1 (DNA encoding a peptide from the N-terminal hairpin loop to the 2 nd kringle domain of HGF).
- Such DNA is not particularly limited to those described above, and includes DNA encoding a peptide that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- the DNA can be easily obtained by, for example, a general hybridization or PCR method. Specifically, the DNA can be obtained with reference to basic manuals, for example, the above-mentioned Third Edition Molecular Cloning and the like.
- Examples of DNA that contains DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue preferably include genomic DNA, genomic DNA library, cell- or tissue-derived cDNA, cell-or tissue-derived cDNA library, synthetic DNA, and the like.
- Examples of vectors used for the cloning of genomic DNA fragments into the above-mentioned library include bacteriophages, plasmids, cosmids, phagemids, and the like.
- any RNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be used as long as HGF protein can be expressed by reverse transcriptase.
- the RNA include RNA obtained by RT-PCR amplification of mRNA fractions harvested from cells or tissues, which is within the scope of the present invention.
- the RNA also can be obtained by known methods.
- the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may contain DNA that encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and that hybridizes under a stringent condition with DNA comprising a base sequence complementary to the DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- Such DNA includes DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF partial peptide, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- DNA examples include DNA that encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and hybridizes under a stringent condition with DNA comprising a base sequence complementary to DNA having a partial base sequence of DNA comprising the base sequence represented by SEQ ID NO: 1 or 2.
- Specific examples of such DNA include DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of DNA encoding a partial peptide of DNA having the base sequence represented by SEQ ID NO: 1 or 2, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated in the same manner as described above.
- hybridization under a stringent condition is the same as defined above.
- Tendon can usually be defined as tissue that connects skeletal muscles to bones
- ligament can usually be defined as tissue that connects bones to bones.
- tendon may include the meaning of a ligament that connects bones to bones.
- the tendon used in the present invention may include a graft of tendon (hereinafter sometimes referred to as a "tendon graft”)
- the ligament used in the present invention may include a graft of ligament (hereinafter sometimes referred to as a "ligament graft").
- Tendon grafts may be tendon autografts or allografts.
- tendon autografts to be used may be taken from hamstrings, patellar tendons, or femoral flexor tendons.
- Tendon allografts generally used are extracted from cadavers, particularly from their hamstrings, patellar tendons, femoral flexor tendons, Achilles tendons, tendons of tibiae or elbows, etc.
- Synthetic (or artificial) tendon grafts or tendon xenografts may be used.
- Tendon grafts in which a tendon autograft (or tendon allograft) is hybridized with a synthetic tendon graft etc. may be used. The tendon graft may be multiply folded for use.
- Ligament grafts may be ligament autografts or allograft.
- ligament autografts to be used may be extracted from iliotibial tracts etc.
- Ligament allografts generally used are extracted from cadavers, particularly from their iliotibial tracts, medial collateral ligaments (MCLs), lateral collateral ligaments (LCLs), anterior cruciate ligaments (ACLs), posterior cruciate ligaments (PCLs), outside ligaments, triangular ligaments, tibiofibular ligaments, coracoclavicular ligaments, ligaments of the heads of femora, and the like.
- Synthetic (or artificial) ligament grafts or ligament xenografts may be used.
- Ligament grafts in which a ligament autograft (or allograft) is hybridized with a synthetic ligament graft may be used. The ligament graft may be multiply folded for use.
- the "tendon-bone junction” and “ligament-bone junction” are not particularly limited as long as they refer to a region in which a tendon or a ligament is adhered to (fixated or fused with) a bone. Examples thereof include a region where a tendon graft is adhered to the inner surface of a bone tunnel (hole) that is made for securing the tendon graft in ligament reconstructive surgery.
- the bone tunnel is drilled using, for example, a drill guide, drill, etc.
- ligament reconstructive surgery include ligament reconstructive surgery of the knee joint, ankle joint, elbow joint, wrist joint, shoulder joint, and the like.
- ACL anterioral ligament reconstructive surgery
- PCL posterioral ligament reconstructive surgery
- MPFL reconstructive surgery for recurrent patellar dislocation
- lateral ankle ligament reconstructive surgery e.g., lateral ankle ligament reconstructive surgery
- ulnar elbow ligament reconstructive surgery e.g., surgery for repairing the rotator cuff of the shoulder joint, and the like.
- a bone tunnel is established at the upper end (proximal end) of the tibia and the lower end of the femur.
- the tendon graft is passed through the bone tunnel and secured so that the graft runs between the tibia and the femur while having substantially the same function as the original ACL. Since the tendon-bone junction tissue is reconstructed at a site where the immobilized tendon graft is in contact with the inner surface of the bone tunnel, or in a space between the tendon graft and the bone tunnel, the tendon graft can serve as a ligament, allowing the recovery of the normal function of the knee joint. Thereby, a ligament is reconstructed between the tibia and the femur.
- Immobilization can be performed using a bone screw (interference fit screw) or a similar fastener, a ligament fastener, suture (for example, nylon thread, silk thread, etc.), etc.
- a fastener, ligament fastener, and suture can be used alone or in combination.
- the ligament fastener include a stainless steel washer (produced by Zimmer K.K.), Endo Button (produced by Smith and Nephew Endoscopy Co., Ltd.), etc.
- the tendon-bone junction or the ligament-bone junction has complicated anatomic features; for example, they include a collagen fiber layer that contains Sharpey-like fibers.
- Regeneration indicates that tendon-bone junction tissue or ligament-bone junction tissue is reconstructed.
- "regeneration” includes any condition in which the grafted tendon (or grafted ligament) having sufficient strength is adhered to (fixated or fused with) a bone, and physiologically functions in vivo. Regeneration of the tendon-bone junction tissue or the ligament-bone junction tissue includes the following steps (1) to (5):
- the promoter for regenerating tendon-bone junction tissue or ligament-bone junction tissue of the present invention can be classified into (a) a promoter comprising HGF protein/partial peptide as an active ingredient, and (b) a promoter comprising a HGF gene as an active ingredient.
- HGF protein/partial peptide A promoter that comprises as an active ingredient, HGF protein as explained in Item (2) above, partial peptide of HGF protein (HGF partial peptide) as explained in Item (3) above, or a salt of at least one of the HGF protein or partial peptide (hereinbelow sometimes referred to as "HGF protein/partial peptide").
- a promoter comprising as an active ingredient, DNA encoding HGF protein as explained in Item (4) above, (5) DNA hybridizing with the DNA under a stringent condition, DNA encoding HGF partial peptide as explained in Item (6) above, (7) DNA hybridizing with the DNA under a stringent condition (hereinafter, each refereed to as "HGF gene").
- the dosage form, dosing method, dose, etc. may vary when the aforementioned "HGF protein/partial peptide" is used as an active ingredient or the aforementioned "HGF gene" is used as an active ingredient.
- the dosage form, dosing method, dose, etc. , of the promoter of the present invention can be suitably designed or modified depending on the type of active ingredient.
- the promoter (a) can be in any of various dosage forms such as a liquid or solid form.
- HGF protein, HGF partial peptide, or a salt thereof is formulated in combination with a known carrier into an injection, spray, sustained-release formulation (for example, depot formulation), or the like.
- the injection or spray may be an aqueous or oily formulation.
- the aqueous injection can be prepared by known methods.
- an aqueous solvent such as water for injection and purified water
- a pharmaceutically acceptable additive such as a tonicity agent (e.g., sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose, and propylene glycol), a buffer solution (e.g., phosphate buffer solution, acetate buffer solution, borate buffer solution, carbonate buffer solution, citrate buffer solution, Tris-buffer solution, glutamic acid buffer solution, and epsilon-aminocaproic acid buffer solution), a preservative (e.g., methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, and bo
- an appropriate solubilizing agent such as an alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, and polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80 and polyoxyethylene 50 hydrogenated castor oil) or the like may also be added.
- an alcohol e.g., ethanol
- polyalcohol e.g., propylene glycol, and polyethylene glycol
- a nonionic surfactant e.g., polysorbate 80 and polyoxyethylene 50 hydrogenated castor oil
- sesame oil, soy bean oil, or the like may be used as an oily solvent, and benzyl benzoate, benzyl alcohol, or the like may be added as a solubilizing agent.
- the prepared injection is usually filled into an appropriate ampoule, vial, etc.
- the amount of the HGF protein in the injection is not limited, but usually can be adjusted to about 0.0002 to 0.5 w/v%, preferably about 0.001 to 0.2 w/v%, based on the total amount of the injection.
- a liquid formulation such as an injection is preferably freeze-stored, or stored after removing moisture by lyophilization or the like.
- the lyophilized formulation can be used by adding distilled water for injection or the like as needed and redissolving the formulation.
- a spray also can be prepared by common methods in the formulation practice.
- any additive may be added to the spray as long as the additive is usually used for an inhaled formulation.
- the above-mentioned solvent, preservative, stabilizer, tonicity agent, pH adjuster, etc. can be added.
- the propellant include a liquefied gas propellant or a compressed gas.
- the liquefied gas propellant include a fluorohydrocarbon (e.g. alternative freon such as HCFC22, HCFC-123, HCFC-134a, dHCFC142, etc.), liquefied petroleum, dimethyl ether, or the like.
- the compressed gas examples include a soluble gas (e.g., carbon dioxide gas and nitrous oxide gas) and an insoluble gas (e.g., nitrogen gas).
- a soluble gas e.g., carbon dioxide gas and nitrous oxide gas
- an insoluble gas e.g., nitrogen gas.
- the amount of the HGF protein in the spray usually can be adjusted to about 0.0002 to 5 w/v%, preferably about 0.001 to 2 w/v%, based on the total amount of the spray.
- the HGF protein/partial peptide used in the present invention can be formulated into a sustained-release formulation (e.g., a depot formulation) together with a biodegradable polymer.
- a depot formulation of HGF protein/partial peptide can be expected to reduce dose frequency, prolong effects, and reduce side effects.
- the sustained-release formulation can be prepared by known methods.
- the biodegradable polymer to be used in the sustained-release formulation can be appropriately selected from known biodegradable polymers, for example, polysaccharides such as starch, dextran, or chitosan; proteins such as collagen or gelatin; polyamino acids such as polyglutamic acid, polylysine, polyleucine, polyalanine, or polymethionine; polyesters such as polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, polycaprolactone, poly- ⁇ -hydroxybutyric acid, polymaleic acid, polyanhydride, or fumaric acid-polyethylene glycol-vinylpyrrolidone copolymer; polyortho esters; polyalkyl cyanoacrylates such as polymethyl- ⁇ -cyanoacrylate; polycarbonates such as polyethylene carbonate or polypropylene carbonate.
- biodegradable polymers for example, polysaccharides such as starch, dextran, or chitosan; proteins
- Preferable examples include polyester, polylactic acid, and a lactic acid-glycolic acid copolymer; and more preferable examples include polylactic acid and a lactic acid-glycolic acid copolymer.
- the composition ratio based on the mole percentage varies depending on the duration of sustained release. For example, when the duration of sustained release is from about 2 weeks to 3 months, preferably from about 2 weeks to 1 month, the preferable ratio is from about 100/0 to 50/50.
- the weight-average molecular weight of the polylactic acid or lactic acid-glycolic acid copolymer is preferably from about 5,000 to 20,000.
- the polylactic acid or lactic acid-glycolic acid copolymer can be prepared by known methods, for example, the method disclosed in Japanese Unexamined Patent Publication No. S61-28521 .
- the addition ratio of HGF protein and the biodegradable polymer is not particularly limited, but the amount of the HGF protein is generally from about 0.001 to 50 w/w%, and preferably from about 0.01 to 30 w/w%, relative to the biodegradable polymer.
- Preferable dosing methods include topical application (direct injection or spray) of an injection or spray to a region (interface) where the bone is in contact with the tendon or ligament graft, or a space between the bone and the tendon or ligament graft, or the surrounding area, and topical application (embedding) of a sustained-release formulation (depot formulation) to the interface or its surrounding area.
- the dose is appropriately selected according to dosage form, disease progression, age, or the like, and the amount of HGF protein included in the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention is usually 0.1 ⁇ g to 500 mg, preferably 1 ⁇ g to 50 mg, more preferably 10 ⁇ g to 25 mg per dose.
- the dose frequency is also appropriately selected according to dosage form, disease progression, age, or the like.
- a single dosing or continuous dosing at a certain interval can be selected.
- the continuous dosing may be performed between once daily and once every several months.
- dosing with the sustained-release formulation (a depot formulation) or continuous dosing with a sustained-release pump may be performed once every several months.
- the HGF gene is delivered to a patient in compliance with conventional methods, for example, the method described in " Idenshi Chiryo No Kiso-gijyutsu (Basic Technique for Gene Therapy)", a separate volume of Experimental Medicine, Yodosha Co., Ltd., 1996 ; “ Idenshi Dounyu & Hatsugen Kaiseki Jikken-hou (Experimental Method for Gene Delivery and Expression Analysis)", a separate volume of Experimental Medicine, Yodosha Co., Ltd., 1997 ; and " Idenshi Chiryo Kaihatsu Kenkyu Handbook (Handbook for Research & Development in Gene Therapy)” edited by the Japan Society of Gene Therapy, NTS Inc., 1999 ; etc.
- topical application topical injection of a recombinant expression vector in which the HGF gene is introduced to the interface or its surrounding tissue (for example, bone, muscle, etc.).
- the expression vector examples include, but are not limited to, naked plasmids, and DNA or RNA viruses such as detoxified retroviruses, adenoviruses, adeno-associated viruses, herpes viruses (herpes simplex virus type 1, etc.), vaccinia viruses, poxviruses, polioviruses, Sindbis viruses, Sendai viruses, SV40, human immunodeficiency viruses (HIV), etc.
- HSV-1 herpes simplex virus type 1
- HVJ-E Sendai virus envelope
- AAV adeno-associated virus
- a specific HSV-1 vector includes a replication-incompetent HSV-1 (HSV1764/4-/pR19) vector that is severely impaired by the deletion of the three respective genes encoding ICR4, ICP34.5 and VP16 (vmw65), all of which are essential for viral replication (see also Coffin, R.S. et al., J. Gen. Virol. 1998, Vol. 79, pp. 3019-3026 ; Palmer, J. A. et al., J. Virol., 2000, Vol. 74, pp. 5604-5618 ; Lilley, C. E. et al. , J. Virol. , 2001, Vol. 75, pp. 4343-4356 ; etc.).
- the HVJ-E vector is produced, for example, by the method described in US Patent No. 6,913,923 .
- the HVJ-E vector GenomONE-Neo EX HVJ Envelope Transfection Kit (produced by Cosmo Bio Co., Ltd.) is preferably used.
- the AAV vector which is a non-pathogenic virus, is highly safe and efficient in gene delivery into a cell.
- the AAV vector include AAV-2, AAV-4, and AAV-5.
- Such an HSV-1, HVJ-E, or AAV vector is capable of expressing the target gene in a safe manner for a prolonged period of time.
- An HSV-1, HVJ-E, or AAV vector capable of safe and prolonged expression is most preferable as a vector used in the present invention.
- the form of delivering HGF gene into a patient can be selected from various known forms (for example, an injection, spray, sustained-release formulation (depot formulation), microcapsule, etc.) in response to each of the above-mentioned dosing methods.
- the injection, spray, and sustained-release formulation (depot formulation) can be prepared in the same manner as described in the section HGF protein.
- the amount of HGF gene delivery vector varies depending on the type of the HGF gene delivery vector and is not limited. For example, when the formulation is in the form of an injection, the amount of gene delivery vector can be generally adjusted to about 1 x 10 5 to 1 x 10 12 pfu/mL, and preferably about 1 x 10 6 to 1 x 10 11 pfu/mL.
- a microcapsule can be prepared as a fine particle with a diameter of about 1 to 500 ⁇ m, preferably about 100 to 400 ⁇ m, by coating a core substance, for example, a host cell etc., transfected with the HGF gene-containing expression plasmid, with a coating material in accordance with known methods (for example, a coacervation method, interfacial polycondensation, and a method using a double nozzle).
- the coating material examples include a membranous polymer such as carboxymethyl cellulose, cellulose acetate phthalate, ethyl cellulose, alginic acid and a salt thereof, gelatin, gelatin-gum arabic, nitrocellulose, polyvinyl alcohol, hydroxypropyl cellulose, polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, chitosan-alginate, cellulose sulfate-poly(dimethyldiallyl)ammonium chloride, hydroxyethyl methacrylate-methyl methacrylate, chitosan-carboxymethyl cellulose, alginate-polylysine-alginate, and the like.
- a membranous polymer such as carboxymethyl cellulose, cellulose acetate phthalate, ethyl cellulose, alginic acid and a salt thereof, gelatin, gelatin-gum arabic, nitrocellulose, polyvinyl alcohol, hydroxy
- the amount of HGF gene in the formulation and its dose are appropriately adjusted depending on the type of disease intended to be treated, the age and body weight of the patient, etc.
- the dose can vary depending on the kind of the HGF gene delivery vector.
- the HGF gene delivery vector is usually administered in an amount of 1 x 10 6 pfu to 1 x 10 12 pfu, preferably 1 x 10 7 pfu to 2 x 10 11 pfu, more preferably 1.5 x 10 7 pfu to 1.5 x 10 11 pfu once every several days to once every several months.
- the promoter of the present invention is suitably applied to humans, as well as other mammals, such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, chimpanzees, etc.
- the promoter of the present invention is preferably used at a site (interface) where the bone is in contact with the tendon or ligament graft after surgery, or in the surrounding area.
- the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention can regenerate tendon-bone junction tissue or ligament-bone junction tissue in the interface or the space between the bone and the tendon or ligament graft.
- EDL extension digitorum longus
- the free end of the EDL tendon (tendon graft) that had been previously cut was pulled into the bone tunnel from the lateral surface of the tibia, then pulled out of the medial surface of the tibia, and secured using a stainless steel washer (produced by Zimmer K.K.) and a 3-0 nylon thread (produced by Bear Medic Corporation). The leg was secured in ankle neutral position. The bone tunnel into which the tendon graft had been pulled was fully washed with physiological saline solution (produced by Otsuka Pharmaceutical Co., Ltd.).
- cancellous bone containing 10 ⁇ L of a mixture obtained by dissolving 10 ⁇ g of HGF protein in 10 ⁇ L of physiological saline was transplanted to the contact site and space between the bone tunnel and the tendon graft of the right hind leg (HGF administration group).
- HGF protein HGF protein having the amino acid sequence represented by SEQ ID No. 6 was used.
- cancellous bone containing 10 ⁇ L of physiological saline was transplanted (control group).
- the cancellous bone collected in the formation of the bone tunnel was used as the cancellous bone (0.05 g).
- the wound was closed by suture.
- the rabbits were returned to their cages, and were free to move about without any restriction or immobilization of their extremities.
- the tendon graft including the tibia and EDL was taken as a lump of tissue.
- the distance from the entrance (lateral surface) to the outlet (medial surface) of the hole (bone tunnel) of the proximal tibia was measured using a caliper.
- Four rabbits were used for histological examination and five rabbits were used for biomechanical testing.
- the extracted tissue was preserved in a 10% (v/v) formalin solution for 2 days, washed with physiological saline, and then immersed in 80% (v/v) methyl alcohol for two days. Subsequently, decalcification was performed using a Plank-Rychlo solution over 7 days. After decalcification, sections were made along the long axis of the bone tunnel of the tibia. The obtained sections were stained with hematoxylin-eosin(HE) and Masson trichrome. The stained sections were observed with an optical microscope and scored using the following criteria.
- Score Criteria - The formation of new tissue was not observed in the interface (the contact site and the space between the tendon graft and the bone tunnel).
- FIG. 2 shows optical micrographs at 8 weeks after surgery.
- the HGF administration group (right figure A) clearly indicates that Sharpey-like fibers and collagen fibers that were oriented toward the bone appeared in the interface. Additionally, the Sharpey-like fibers matured into thick fibers.
- Table 1 shows the interface tissue score. Table 1 clearly indicates that, in the HGF administration group, the formation (regeneration) of tendon-bone junction tissue in the interface was promoted at an early postoperative stage.
- Biomechanical testing was carried out by comparing the rupture strength of tendon-bone junction tissue formed when the tendon graft was attached to the bone tunnel.
- Rupture strength N / mm Ultimate load / Bone tunnel length
- the ultimate load is obtained as follows. Using a tensile testing machine (4482 model, produced by Instron Co., Ltd.), the tibia of the extracted tissue was secured to the tensile testing machine, and then the EDL was held and pulled along the long axis of the bone tunnel. The load obtained when the tendon graft was pulled out of the bone tunnel was expressed as the ultimate load. Tendon grafts that had ruptured before being pulled out of the bone tunnel were excluded.
- Table 2 shows the rupture strength at 2 and 6 weeks after surgery. At both 2 and 6 weeks after surgery, the rupture strength in the HGF administration group was higher than in the control group.
- Example 1 An experiment was conducted in the same manner as in Example 1 except that the HGF protein having the amino acid sequence represented by SEQ ID NO: 4 was used in place of the HGF protein used above. The results reveal that the HGF protein had the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in Example 1.
- HGF protein having an amino acid sequence represented by SEQ ID Nos. 3 to 6 can be used as HGF protein.
- the solution was placed in a vial in an amount of 1 mL, freeze-dried, and sealed to obtain a promoter in the form of a freeze-dried formulation.
- aqueous solution in which 1 mg of HGF protein (SEQ ID No. 6) and 100 mg of human serum albumin were added to 100 mL of 0.02 M phosphate buffer solution was aseptically prepared.
- the aqueous solution was placed in a vial in an amount of 1 mL, freeze-dried, and sealed to obtain a promoter in the form of a freeze-dried formulation.
- 100 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion.
- the dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture was stirred and emulsified using a homomixer.
- Dichloromethane is then vaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. Themixture is then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days. Thereby, sustained release microcapsules containing HGF protein are obtained (the addition ratio of HGF to biodegradable polymer: 5.3 w/w%).
- 10 mg of zinc oxide are dissolved in 3.0 mL of dichloromethane.
- 100 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion.
- the dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixtureis stirred and emulsified using a homomixer.
- Dichloromethane is then vaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture was then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days. Thereby, sustained release microcapsules containing HGF protein are obtained (the addition ratio of HGF to biodegradable polymer: 5.3 w/w%).
- dichloromethane 300 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion.
- the dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture is stirred and emulsified using a homomixer.
- Dichloromethane isvaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules (about 2,000 rpm). Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture is then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days to obtain a sustained release microcapsule containing HGF protein (the addition ratio of HGF to biodegradable polymer: 17.6 w/w%).
- 10 mg of zinc oxide are dissolved in 2.7 mL of dichloromethane.
- 300 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion.
- the dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture was stirred and emulsified using a homomixer.
- Dichloromethane is vaporized by stirring at room temperature for 3 hours and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture was then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days to obtain sustained release microcapsules containing HGF protein (the addition ratio of HGF to a biodegradable polymer: 17.8 w/w%).
- methylene chloride 50 mL
- 2.5 mg of freeze-dried HGF protein powder is added to the mixture.
- the resulting mixture is added to a 0. 5 w/v% chitosan aqueous solution that had been separately heated to 40°C, and stirred and emulsified by a homomixer at a stirring rate of 1000 rpm.
- the emulsion obtained is further stirred for 3 hours at room temperature to evaporate methylene chloride.
- microspheres obtained by centrifuging (about 2,000 rpm) are collected and washed five times with distilled water that had been heated to 40°C. Subsequently, drying under reduced pressure is carried out at room temperature, and microspheres containing HGF are obtained (the addition ratio of HGF to biodegradable polymer: 0.05 w/w%).
- microspheres obtained by centrifuging (about 2,000 rpm) are collected.
- the collected microspheres are washed five times with distilled water that had been heated to 40°C, and dried under reduced pressure at room temperature to obtain microspheres containing HGF protein (the addition ratio of HGF to biodegradable polymer: 0.025 w/w%).
- HGF-containing aqueous solution 0.2 mL of 2 w/v% HGF-containing aqueous solution and 2 mL of 2 w/v% atelocollagen-containing phosphate buffer solution are mixed and freeze-dried.
- the HGF-containing aqueous solution can be prepared by the method according to Preparation Example 1.
- the resulting freeze-dried product is pulverized under low temperature using liquid nitrogen, and then subjected to molding compression using a mold to obtain a cylindrical sustained release formulation containing HGF protein (the addition ratio of HGF to a biodegradable polymer: 10 w/w%).
- HGF protein 1 mg is dissolved in 2 mL of 2 w/v% atelocollagen solution, and the mixture is freeze-dried. The resulting freeze-dried product is pulverized, and then subjected to compression molding to form a cylindrical shape.
- the sustained release formulation containing HGF protein is thus obtained (the addition ratio of HGF to biodegradable polymer: 2.5 mass%).
- 0.58 g of sodium salt of hyaluronan (limiting viscosity number: 45, 000 cc/g) and 20 mL of water are mixed and allowed to swell.
- 2 mL of 2N sodium hydrate is added to the mixture, and stirred to form a homogeneous solution.
- a solution prepared by adding 0.10 g of divinyl sulfone to 2.4 mL of water while stirring is added to the aforementioned solution to form a mixture.
- the mixture is allowed to stand for 70 min to obtain a gel.
- the gel is introduced into 223 mL of BioTris buffer solution (0.15M NaCl phosphate buffer, pH: about 7.2) and allowed to swell for 3 hours.
- the promoter for the regeneration of a tendon- or ligament-bone junction tissue of the present invention is useful as a medical drug for promoting the regeneration of a tendon- or ligament-bone junction tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
(1-a) HGF protein,
(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
(1-c) a salt of (1-a) or (1-b);
(2) DNA including the following (2-a), (2-b), or (2-c),
(2-a) DNA encoding HGF protein,
(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
Description
- The present invention relates to a promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- Recently, injuries such as tendon or ligament ruptures in sports, traffic accidents, etc., are increasing. In regard to ligaments, since the anterior cruciate ligament (ACL) and the posterior cruciate ligament (PCL) are tissues that connect the femur to the tibia through a knee joint, when the ACL or PCL is ruptured, the stability of the knee joint cannot be maintained. Once ruptured, ligaments cannot be oversewn; therefore, in many cases, ligament reconstructive surgery is utilized to repair or replace injured ligaments.
For example, in ACL reconstructive surgery in which a damaged ACL is reconstructed by replacing it with a ligament graft, the patellar tendon with bone blocks is conventionally utilized as a graft. Such ACL reconstructive surgery allows rehabilitation to start early because the patellar tendon can function as a ligament when the bones attach to each other. However, the surgery also has disadvantages such as postoperative pain and muscle weakness. - In recent years, ACL reconstructive surgery that utilizes as a tendon graft, a hamstring tendon (knee flexor tendon, semitendinosus tendon, gracilis tendon), which is one of the muscle tendons used in bending the knees has been reported (for example, see Non Patent Literature 1). More specifically, the surgery includes the steps of forming a bone tunnel (hole) in the upper end of the tibia and the lower end of the femur, placing one end of the tendon graft in the femur side of the bone tunnel, and placing the other end of the tendon graft in the tibia side of the bone tunnel. Thus, the tendon graft runs between the femur and the tibia, and thereby functions. The tendon graft performs substantially the same function as the original ACL, thereby allowing the recovery of normal function in the knee joints. However, since the object of ACL reconstructive surgery is to reconstruct the normal ACL function and the kinematics of the knee joints, it is necessary to reconstruct the tendon-bone joint tissue in the part where the tendon graft comes in contact with the bone surface in the bone tunnel with enough strength.
For this reason, ACL reconstructive surgery has a disadvantage such that a long period of time is required before the tendon graft can function as a ligament.
As a drug for promoting the regeneration of tendon-bone junction tissue, BMP-2 (Bone Morphogenetic Protein-2: Non-Patent Literature 2), TGF-B1 (Transforming Growth Factor-B 1: Non-Patent Literature 3), etc., are known; however, they have not yet been used in practice as a drug for promoting the regeneration of tendon-bone junction tissue. - HGF (Hepatocyte Growth Factor, hereinafter referred to as "HGF protein") was first identified as a potent mitogen for mature hepatocytes, and was determined by DNA cloning in 1989 (Non-Patent Literatures 4 and 5). Thereafter, HGF has been reported as having various effects such as angiogenesis, cell differentiation, cell proliferation, anti-apoptosis, etc., in various tissues. As to its effect in tendon tissue, it is reported that when HGF gene plasmid DNA is introduced into a wound made in the center of rat patellar tendon, the orientation of the developing collagen fibers in the wound is improved (Non-Patent Literature 6). However, tendon-bone junction tissue has a structure different from the tendon itself, and is a complicated tissue to adhere (fixate or fuse) a bone and a tendon, which are completely different from each other histologically. Non-Patent Literature 6 does not disclose or suggest the regeneration of such complicated tendon-bone junction tissue. Further, HGF protein is reported to inhibit the expression of TGF-β1, which, as mentioned previously, is known as a drug that promotes the regeneration of tendon-bone junction tissue (Non Patent Literature 7).
-
- NPL 1: S.A. Rodeo et al., The Journal of Bone and Joint Surgery; JBJS, 1993, Vol. 75-A, .
- NPL 2: S.A. Rodeo et al., The American Journal of Sports Medicine, 1999, Vol. 27, pp. 476-488
- NPL 3: Shuji Yamazaki et al., The Journal of Arthroscopic and Related Surgery; JBJS, 2005, Vol. 21, Issue 9, pp. 1034-1041
- NPL 4: Toshikazu Nakamura et al., Biochemical and Biophysical Research Communications, 1984, Vol. 122, pp. 1450-1459
- NPL 5: Toshikazu Nakamura et al., Nature, 1989, Vol. 342, pp. 440-443
- NPL 6: Takashi Natsu-ume et al., Journal of the Japanese Orthopaedic Association, 1998, Vol. 72, Issue 8, S1254
- NPL 7: Kunio Matsumoto and Toshikazu Nakamura, Biochemical and Biophysical Research Communications, 1997, Vol. 239, pp. 639-644
- An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. Particularly, an object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue at a contact site between a bone and a tendon or ligament graft after ACL reconstructive surgery etc., or in a space between a bone and a tendon or ligament graft after ACL reconstructive surgery etc.
- The present inventors conducted extensive research to solve the above problems. Consequently, they found that HGF protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and accomplished the invention.
- Specifically, the present invention relates to a promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
-
- 1. A promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue, comprising the following (1) or (2) as an active ingredient:
- (1) the following (1-a), (1-b), or (1-c)
- (1-a) HGF (Hepatocyte Growth Factor) protein,
- (1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (1-c) a salt of (1-a) or (1-b);
- (2) DNA comprising the following (2-a), (2-b), or (2-c),
- (2-a) DNA encoding HGF protein,
- (2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- (1) the following (1-a), (1-b), or (1-c)
-
- 2. The promoter according to
Item 1, wherein the active ingredient is the following (1-a), (1-b), or (1-c):- (1-a) HGF protein,
- (1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (1-c) a salt of (1-a) or (1-b).
-
- 3. The promoter according to
Item 1 or 2, wherein the HGF protein is the following (1-d) or (1-e):- (1-d) a protein having an amino acid sequence represented by SEQ ID NO: 3 or 4,
- (1-e) a protein having an amino acid sequence that is substantially equal to an amino acid sequence represented by SEQ ID NO: 3 or 4, and having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- Herein, an example of protein (1-e) includes "a protein that has an amino acid sequence at least 85% homologous to an amino acid sequence represented by SEQ ID NO: 3 or 4, and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue".
-
- 4. The promoter according to
Item 1, wherein the active ingredient is DNA comprising the following (2-a), (2-b), or (2-c):- (2-a) DNA encoding HGF protein,
- (2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
-
- 5. The promoter according to
Item 1 or 4, wherein the DNA encoding HGF protein is the following (2-d) or (2-e):- (2-d) DNA having a base sequence represented by SEQ ID NO: 1 or 2,
- (2-e) DNA that encodes a protein having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and that hybridizes with DNA having a base sequence complementary to the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition.
- 6. The promoter according to any one of
Items - 7. The promoter according to any one of
Items 1 to 6, which is in a form of topical application. - Further, the present invention relates to a use of HGF protein, or DNA encoding HGF protein.
-
- 8. Use of the following (1) or (2) for manufacturing a promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue:
- (1) the following (1-a), (1-b), or (1-c),
- (1-a) HGF protein,
- (1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (1-c) a salt of (1-a) or (1-b),
- (2) DNA comprising the following (2-a), (2-b), or (2-c),
- (2-a) DNA encoding HGF protein,
- (2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- (1) the following (1-a), (1-b), or (1-c),
-
- 9. The following (1) or (2) for use in a method of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue:
- (1) the following (1-a), (1-b), or (1-c),
- (1-a) HGF protein,
- (1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (1-c) a salt of (1-a) or (1-b),
- (2) DNA comprising the following (2-a), (2-b), or (2-c),
- (2-a) DNA encoding HGF protein,
- (2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- (1) the following (1-a), (1-b), or (1-c),
-
- 10. A method for promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue comprising: administering the following (1) or (2) to a patient with tendon-bone junction tissue injury or ligament-bone junction tissue injury:
- (1) the following (1-a), (1-b), or (1-c),
- (1-a) HGF protein,
- (1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (1-c) a salt of (1-a) or (1-b),
- (2) DNA comprising the following (2-a), (2-b), or (2-c),
- (2-a) DNA encoding HGF protein,
- (2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,
- (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- (1) the following (1-a), (1-b), or (1-c),
- The promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention can enhance the regeneration of the tendon-bone junction tissue or the ligament-bone junction tissue at a site in which a bone is in contact with a ligament or tendon graft separated from the bone, or in a space between the bone and the ligament or tendon graft. Thus, the present invention can promote adhesion (fixation or fusion) between a bone and a tendon or ligament that is separated from the bone by injury, rupture, etc.
Further, since the present invention can enhance the regeneration of tendon-bone junction tissue or ligament-bone junction tissue in ligament reconstructive surgery of limb joints (e.g., knee, ankle, elbow, and shoulder) including ACL reconstructive surgery, PCL reconstructive surgery, collateral ligament reconstructive surgery, MPFL (medial patellofemoral ligament) reconstructive surgery, ankle lateral ligament reconstructive surgery, ulnar ligament reconstructive surgery, and tendon repair surgery etc., adhesion (fixation or fusion) between a bone and a tendon or ligament graft can be enhanced.
Therefore, the present invention results in a faster recovery of patients after ligament reconstructive surgery , who have unstable joints because of ligament rupture etc., and thereby have difficulty in sporting activities and daily life. - As described above, "HGF protein" has been identified as a potent mitogen for adult hepatocytes, and is called "Hepatocyte Growth Factor" (see, for example, Non-patent Literatures 4 and 5). In addition to HGF, it is referred to as SF (scatter factor), TCF (Tumor Cytotoxic Factor), etc.
- "HGF protein" as used herein is a known substance, and can be prepared by any method as long as it is purified enough to be used as a medicament.
- HGF protein can be obtained by culturing primary cultured cells or cell lines capable of producing HGF protein, followed by separation of the HGF protein from culture supernatant etc., and purification. Alternatively, the protein can be obtained by genetic engineering techniques, for example, by inserting the gene encoding HGF protein into an appropriate vector, introducing the vector into an appropriate host cell to be transformed, and isolating a desired recombinant HGF protein from the culture supernatant of the transformant, etc. (see, for example, Japanese Unexamined Patent Publication No.
H5-111382 - In the present invention, a preferable example of HGF protein is a protein obtained from a gene encoding human-derived HGF (hHGF). Preferable examples of the gene encoding hHGF include DNA having the base sequence represented by SEQ ID NO: 1 or 2.
- Specific examples of such HGF protein include, according to recombinant DNA techniques, the HGF protein represented by SEQ ID NO: 3 or 5 produced by a cell into which DNA having the base sequence represented by SEQ ID NO: 1 has been introduced, and the HGF protein represented by SEQ ID NO: 4 or 6 produced by a cell into which DNA having the base sequence represented by SEQ ID NO: 2 has been introduced.
- The HGF protein represented by SEQ ID NOs. 3 to 6 is a native HGF protein of human origin having mitogen activity and motogen activity as HGF. Such HGF protein is registered, for example, as Accession No. P14210 (SEQ ID NO: 3) or Accession No. NP_001010932 (SEQ ID NO: 4) in the NCBI database (NCBI-GenBank Flat File Release 164.0), or the like. HGF protein having the amino acid sequence represented by SEQ ID NO: 4 is a five amino acid-deleted HGF protein, in which five amino acid residues, i.e., from the 161st to the 165th residues in the amino acid sequence represented by SEQ ID NO: 3 are deleted. In addition, the aforementioned native HGF protein is glycoprotein. For example, in the HGF protein represented by Accession No. NP_001010932 (SEQ ID NO: 4), a sugar chain is added to Asn 289, Asn 397, Thr 471, Asn 561, and Asn 648.
- The amino acid sequence represented by SEQ ID NO: 5 or 6 is an amino acid sequence of an adult protein obtained by cleaving the 1st to 31st amino acid region (signal sequence) from the N terminus in the amino acid sequence represented by SEQ ID NO: 3 or 4.
- As long as the HGF protein used in the present invention has an effect of promoting the regeneration of tendon-bone junction tissue and ligament-bone junction tissue, one or more ("more" means, for example, 2 to 35 amino acids, preferably 2 to 20 amino acids, and more preferably 2 to 10 amino acids; the same shall apply hereinafter) amino acids in the amino acid sequence represented by SEQ ID NO: 3 or 4 may be deleted, substituted, inserted, or added, and similarly, its sugar chain may be deleted, substituted, inserted, or added. Such HGF protein can be produced by known technical methods such as genetic engineering techniques, site specific mutagenesis, etc. An amino acid to be inserted, substituted, or added may be an unnatural amino acid other than 20 kinds of natural amino acids. The unnatural amino acid may be any compound as long as it has an amino group and a carboxyl group, and for example, γ-amino butyric acid etc., is included. In addition, the HGF protein having the amino acid sequence represented by SEQ ID NO: 4 is, as described above, a five amino acid-deleted type HGF protein, in which five amino acid residues in the amino acid sequence represented by SEQ ID NO: 3 are deleted.
- The HGF protein used in the present invention may have an amino acid sequence at least 85% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 provided that the protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. HGF protein having an amino acid sequence at least 90% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 is preferred, and HGF protein having an amino acid sequence at least 95% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 is more preferred. The amino acid sequence represented by SEQ ID NO: 5 is 95.7% and 96.4% homologous to the amino acid sequence represented by SEQ ID NO: 3 and 4, respectively; and the amino acid sequence represented by SEQ ID NO: 6 is 95.1% and 95.7% homologous to the amino acid sequence represented by SEQ ID NO: 3 and 4, respectively. Herein, "homologous to" indicates the degree of identity between the amino acid residues that form each of the sequences when the primary structures (amino acid sequences) of the proteins are compared.
- Other examples of HGF protein having an amino acid sequence that is highly homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4 include human-derived HGF registered as Accession No. BAA14348 or AAC71655 in the NCBI database.
- As long as the HGF protein used in the present invention has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, the signal sequence comprising the 1st to 31st amino acid region in the amino acid sequence represented by SEQ ID NO: 3 or 4 may be replaced with a signal sequence of another protein. Examples of the signal sequence include a signal sequence of human serum albumin, interferon, human amylase, etc.
- As long as the HGF protein used in the present invention has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, it may be a protein produced by a cell having DNA that hybridizes with DNA comprising a base sequence complementary to the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition.
- The stringent condition is as follows.
Hybridization is carried out at about 65°C in the presence of about 0.7 to 1.0 M sodium chloride, and then washing is conducted at about 65°C in SSC solution at about a 0.1- to 2-fold concentration (a one fold concentration of SSC solution consists of 150 mM sodium chloride and 15 mM sodium citrate). - An example of a method for producing the HGF protein of the present invention using a cell that comprises a gene coding the HGF protein, for example DNA having the base sequence represented by SEQ ID NO: 1 or 2, or DNA that hybridizes with DNA having a base sequence complementary to the aforementioned DNA under a stringent condition is a method in which primary cultured cells or cell lines having the aforementioned DNA are cultured, followed by separation of a desired HGF protein from the culture supernatant etc., and purification. Alternatively, the protein can be obtained by genetic engineering techniques, for example, by inserting the aforementioned DNA into an appropriate vector, introducing the vector into an appropriate host cell to be transformed, and isolating a desired HGF protein (recombinant protein) from the culture supernatant of the transformant (see, for example, Japanese Unexamined Patent Publication No.
H5-111382 H11-1499 - The aforementioned host cell is not particularly limited and various host cells conventionally used in genetic engineering techniques, for example, Escherichia coli, yeast, animal cells, and the like can be used. Since native HGF protein is a glycoprotein, it is preferred to use an animal cell as a host cell to produce glycoprotein as in the case of using a cell.
Examples of the animal cell include CHO cells, COS cells, mouse L cells, mouse C127 cells, mouse FM3A2 cells, and the like. The expression vector is introduced into an animal cell by transfection methods, microinjection methods, etc. Of these, the most commonly used method is a phosphoric-acid calcium method. For the animal cell that is transformed by transfection, floating cultivation, or adhesion cultivation can be used in accordance with an ordinary method. As a medium, MEM, RPMI 1640, and the like are commonly used. - Whether the HGF protein has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be evaluated as follows.
For example, at least a bone and a tendon or ligament separated from the bone are kept immobilized using a ligament fastener etc. The target HGF protein is then reacted according to the method described in the Example below. Compared to the case where nothing is reacted (control), if effective regeneration of tendon-bone junction tissue or ligament-bone junction tissue is observed when the HGF protein is reacted, the HGF protein is considered to have an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. - The presence or absence of glycosylation, and the number of glycosylation sites are not particularly limited as long as the HGF protein used in the present invention has an effect of enhancing bone elongation.
Specifically, the HGF protein may be protein in which naturally occurring sugar chains (one or more) are deleted, substituted, inserted or added. Examples of the HGF protein in which a sugar chain is deleted, substituted, inserted, or added include HGF protein in which a sugar chain attached to native HGF protein has been deleted by treatment with an enzyme or the like, HGF protein in which the amino acid sequence at the glycosylation site has been mutated so as to prevent glycosylation, or HGF protein in which the amino acid sequence has been mutated so that glycosylation occurs at any other site than the naturally-occurring glycosylation site. Specific examples of such HGF protein include HGF protein that is designed to prevent glycosylation by replacing Asn289, Asn397, Thr471, Asn561, and Asn648 with Gln289, Gln397, Gly471, Gln561, and Gln648, respectively in human HGF protein registered as Accession No. NP_001010932 in the NCBI database (NCBI-GenBank Flat File Release 164.0) (Fukuta, K. et al., Biochemical Journal, 2005, Vol. 388, pp. 555-562). - The HGF protein used in the present invention has any one of a carboxyl group (-COOH), a carboxylate (-COOM (M represents a metal)), an amide (-CONH2), or an ester (-COOR) in the C-terminus. Herein, R in the ester may be a C1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; a C3-8 cycloalkyl group such as cyclopentyl and cyclohexyl; a C6-12 aryl group such as phenyl and α-naphthyl; a C7-14 aralkyl group such as a phenyl-(C1-2 alkyl) group including benzyl and phenethyl, and an α-naphthyl-(C1-2 alkyl) group including α-naphthylmethyl; a C2-6 alkanoylmethyl group such as acetyloxymethyl and pivaloyloxymethyl; etc.
- When the HGF protein used in the present invention has a carboxyl group or a carboxylate in any other site than the C-terminus, the carboxyl group or carboxylate may be amidated or esterified. Such HGF protein is also included in the HGF protein used in the present invention. In this case, examples of the ester include the above-mentioned examples of the ester in the C-terminus.
- The HGF protein used in the present invention includes the above-mentioned protein having an amino group of the N-terminal methionine residue protected with a protecting group (for example, a C1-6 acyl group including a formyl group and a C2-6 alkanoyl group such as acetyl, etc.), the above-mentioned protein having a glutamyl group pyroglutamated after being produced by cleaving the N-terminal side in vivo, the above-mentioned protein having a side chain reactive group of the amino acid in a molecule (for example, -OH, -SH, an amino group, an imidazolyl group, an indolyl group, a guanidino group, etc.) protected with an appropriate protecting group (for example, a C1-6 acyl group including a formyl group and a C2-6 alkanoyl group (e.g., acetyl), etc.), and a complex protein such as a glycoprotein, which is produced by glycosylating the above-mentioned protein.
- As the HGF protein used in the present invention, the above-mentioned protein of human origin is suitably used for human application. In addition, HGF protein derived from mammals other than humans, such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, and chimpanzees, may be used.
- Such HGF protein includes, but is not limited to, HGF protein registered in the NCBI database, for example, mouse HGF protein (for example, registered as Accession No. AAB31855, NP_034557, BAA01065, BAA01064, or the like), rat HGF protein (for example, registered as Accession No. NP_058713, bovine HGF protein (for example, registered as Accession No. NP_001026921, BAD02475, or the like), feline HGF protein (for example, registered as Accession No. NP_001009830, BAC10545, BAB21499, or the like), canine HGF protein (for example, registered as Accession No. NP_001002964, BAC57560, or the like), chimpanzee HGF protein (for example, registered as Accession No. XP 519174 or the like), etc.
- When the HGF protein is used as the active ingredient of the promoter of the present invention, the HGF protein can be produced by any methods as long as it is purified enough to be used as a medicament. The purification methods are not limited, and examples thereof include column chromatography using heparin sepharose, hydroxyapatite, etc.
- In the promoter of the present invention, HGF protein may be used alone, or as a mixed protein with various proteins as long as the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue is not impaired.
- The partial peptide of HGF protein used in the present invention (sometimes hereinafter abbreviated as HGF partial peptide), the peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue is not limited as long as it is a partial peptide of the aforementioned HGF protein and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the aforementioned HGF protein. In the present invention, the HGF partial peptide has an amino acid sequence that constitutes the above-mentioned HGF protein and comprises about 20 amino acids or more, preferably about 50 amino acids or more, and more preferably about 100 amino acids or more. Specifically, examples of such an HGF partial peptide include a peptide having an amino acid sequence between the 32nd and the 210th residues from the N-terminus in the human HGF amino acid sequence represented by SEQ ID NO: 3 (an amino acid sequence from the N-terminal hairpin loop to the 1st kringle domain of HGF), a peptide having the amino acid sequence between the 32nd and the 288th residues from the N-terminus in the human HGF amino acid sequence represented by SEQ ID NO: 3 (an amino acid sequence from the N-terminal hairpin loop to the 2nd kringle domain of HGF), and the like.
- Examples of the HGF partial peptide of the present invention include a partial peptide having an amino acid sequence at least about 80%, preferably at least about 90%, and more preferably at least about 95% homologous to the amino acid sequence of the aforementioned HGF partial peptide, and having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- The HGF partial peptide of the present invention has any one of a carboxyl group (-COOH), a carboxylate (-COOM (M is the same as defined above)), an amide (-CONH2), or an ester (-COOR (R is the same as defined above)) in the C-terminus. Further, as in the above-mentioned HGF protein, the HGF partial peptide includes a peptide having an amino group of the N-terminal methionine residue protected with a protecting group, a peptide having a glutamyl group pyroglutamated after being produced by cleaving the N-terminal side in vivo, a peptide having a side chain substituent group of the amino acid within a molecule protected with an appropriate protecting group, and a complex protein such as a glycoprotein, which is produced by glycosylating the above-mentioned peptide.
- Regarding the HGF partial peptide, "an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above.
- The HGF partial peptide of the present invention can be prepared by known peptide synthesis methods or by cleaving HGF protein with an appropriate peptidase. A peptide synthesis method may be, for example, a solid- or liquid-phase synthesis method. Namely, the desired peptide can be prepared by condensing a partial peptide or an amino acid that is capable of constituting HGF protein and optionally having a protecting group with a remaining part optionally having a protecting group; and then by removing the protecting group, if any, from the product. Known condensation or protecting group removal methods include those described in, for example, M. Bodanszky and M. A. Ondetti, Peptide Synthesis, Interscience Publishers, New York (1966); Schroeder and Luebke, The Peptide, Academic Press, New York (1965); etc. After the reaction, HGF partial peptide can be separated and purified by a combination of ordinal purification methods such as solvent extraction, distillation, column chromatography, liquid chromatography, crystallization, or recrystallization.
- The HGF protein or its partial peptide of the present invention may be in a free form (loose body), or the form of a salt.
Examples of the salt of HGF protein or its partial peptide used in the present invention include salts that are physiologically acceptable with an acid or base. Particularly, physiologically acceptable acid adduct salts are preferred. Examples of such salts include salts with inorganic acid (such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, and the like) and salts with organic acid (such as acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, and the like). - In the production, when the HGF protein or the HGF partial peptide of the present invention is used in a free form, it can be converted into an appropriate salt by a known method. Meanwhile, when the HGF protein or HGF partial peptide is obtained in the form of a salt, it can be converted into a free form by a known method.
- Herein, "DNA encoding HGF protein" refers to DNA capable of expressing the HGF protein. Preferable examples of DNA that contains DNA encoding HGF protein include DNA encoding human-derived HGF protein described in, for example, Nature, Vol. 342, p. 440 (1989); Japanese Patent No.
2777678 - As DNA encoding HGF protein used in the present invention, the above-mentioned DNA of human origin is suitably used for human application. In addition, DNA encoding HGF protein derived from mammals other than humans, such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, and chimpanzees may be used.
- Such DNA encoding HGF protein includes, but is not limited to, those registered in the NCBI database, for example, DNA encoding mouse HGF protein (for example, registered as Accession Nos. S71816, M_010427, D10213, D10212, or the like), DNA encoding rat HGF protein (for example, registered as Accession No. NM_017017 or the like), DNA encoding bovine HGF protein (for example, registered as Accession Nos. NM_001031751, AB110822, or the like), DNA encoding feline HGF protein (for example, registered as Accession Nos. NM_001009830, AB080187, AB046610, or the like), DNA encoding canine HGF protein (for example, registered as Accession Nos. NM_001002964, AB090353, or the like), and DNA encoding chimpanzee HGF protein (for example, registered as Accession No. XM_519174 or the like).
- Specific examples of DNA encoding HGF protein include DNA having the base sequence represented by SEQ ID NO: 1 or 2. The base sequence represented by SEQ ID NO: 1 corresponds to the region from the 73rd to the 2259th of the base sequence registered as Accession No. M60718, and also corresponds to DNA encoding HGF protein having the amino acid sequence represented by SEQ ID NO: 3. In recombinant DNA techniques, the HGF protein (SEQ ID NO: 3) that is expressed and produced in a cell is converted into adult HGF protein having the amino acid sequence represented by SEQ ID NO: 5 because the signal sequence is cleaved when the HGF protein is secreted outside the cell. Accordingly, DNA having the base sequence represented by SEQ ID NO: 1 corresponds to DNA encoding (producing) HGF protein having the amino acid sequence represented by SEQ ID NO: 5.
The base sequence represented by SEQ ID NO: 2 corresponds to the region from the 66th to the 2237th of the base sequence registered as Accession No. M73240, and corresponds to DNA encoding HGF protein comprising the amino acid sequence represented by SEQ ID NO: 4. Similarly, in recombinant DNA techniques, the HGF protein (SEQ ID NO: 4) is converted into adult HGF protein having the amino acid sequence represented by SEQ ID NO: 6 because the signal sequence is cleaved when the HGF protein is secreted outside the cell. Accordingly, DNA having the base sequence represented by SEQ ID NO: 2 corresponds to DNA encoding (producing) HGF protein having the amino acid sequence represented by SEQ ID NO: 6. - DNA encoding HGF protein is not limited to the aforementioned DNA, and any DNA encoding protein having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be used as the DNA encoding HGF protein of the present invention. Herein, "the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above.
- Such DNA is not particularly limited, but examples include DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF protein, and encodes a protein having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- The DNA encoding HGF protein can be easily obtained by a general hybridization method or PCR method using a cDNA library containing the DNA. Specifically, the DNA can be obtained with reference to Molecular Cloning, A laboratory Manual, Third Edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 2001; hereinafter abbreviated as Third Edition Molecular Cloning) and other basic manuals.
- Examples of the cDNA library comprising HGF protein-encoding DNA include a human liver cDNA library, a human spleen cDNA library, a human placentas cDNA library, and the like. These libraries can be commercially available from Clonetech, Co., Ltd. or the like. Other than the above, cDNA libraries produced in compliance with a known method by cell strains or tissue materials that express HGF protein can be used. According to the method described in "Third Edition Molecular Cloning", a λ phage in which such cDNA has been incorporated infects Escherichia coli for culture. The plaque formed is then subjected to plaque hybridization or PCR using, as a probe, an oligonucleotide that is produced by a base sequence based on the partial amino acid sequence of HGF protein, thereby yielding a desired DNA encoding HGF protein.
- In the present invention, RNA encoding HGF protein can also be used as long as the HGF protein can be expressed by reverse transcriptase. Examples of the RNA include RNA obtained by RT-PCR amplification of mRNA fractions harvested from cells or tissues, which is within the scope of the present invention. The RNA also can be obtained by known methods.
- As described below, the DNA encoding HGF protein is administered to a patient in the form of a recombinant expression vector in which DNA is inserted. Examples of the expression vector include, but are not limited to, naked plasmids, and DNA or RNA viruses such as detoxified retroviruses, adenoviruses, adeno-associated viruses, herpes viruses (herpes
simplex virus type 1, etc.), vaccinia viruses, poxviruses, polioviruses, sindbis viruses, Sendai viruses, SV40, and human immunodeficiency viruses (HIV). Of these, herpes simplex virus type 1 (HSV-1) vectors, Sendai virus envelope (HVJ-E) vectors, adenovirus vectors, adeno-associated virus (AAV) vectors, etc., are preferred. - The promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may contain DNA coding protein that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the HGF protein, and hybridizing with DNA comprising a base sequence complementary to the DNA encoding HGF protein under a stringent condition.
Preferred examples of such DNA include DNA coding protein that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and hybridizing with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition. - Herein, "effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above.
- "The DNA that hybridizes under a stringent condition with DNA comprising a base sequence complementary to the DNA encoding HGF protein, or with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2" indicates DNA obtained by using a partial sequence of DNA comprising a base sequence complementary to the DNA encoding HGF protein, or with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 as a probe, and then carrying out colony hybridization, plaque hybridization, or southern blot hybridization. Specifically, DNA identified by the following procedures is included. A filter on which colony- or plaque-derived DNA has been immobilized is subjected to, using the probe, hybridization at about 65°C in the presence of about 0. 7 to 1.0M sodium chloride, and then the filter is washed at about 65°C in SSC solution at about 0.1- to 2-fold concentration (a one fold concentration of SSC solution consists of 150 mM sodium chloride and 15 mM sodium citrate). The stringent condition will be the same hereinafter.
- Specifically, DNA that hybridizes under such a stringent condition includes DNA having a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF protein. More specifically, DNA that hybridizes with DNA comprising a base sequence complementary to the DNA having the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition includes DNA having a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence represented by SEQ ID NO: 1 or 2.
- Hybridization can be performed according to known methods, for example the method described in Molecular Cloning, Third Edition. When a commercially available library is used, hybridization also can be performed in compliance with the method described in the attached instruction manual.
- The promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may include DNA encoding HGF partial peptide that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. Herein, "effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above.
- The DNA is not limited as long as it encodes a peptide that has a base sequence encoding the partial peptide and has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. Specifically, examples of the DNA include DNA that has a partial base sequence of DNA having the base sequence represented by SEQ ID NO: 1 or 2, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in the HGF protein.
- Preferred examples of the DNA include DNA having the region from the 94th to the 630th of the human HGF base sequence represented by SEQ ID NO: 1 (DNA encoding a peptide from the N-terminal hairpin loop to the 1st kringle domain of HGF protein), and DNA having the region from the 94th to the 864th of the human HGF base sequence represented by SEQ ID NO: 1 (DNA encoding a peptide from the N-terminal hairpin loop to the 2nd kringle domain of HGF).
- Such DNA is not particularly limited to those described above, and includes DNA encoding a peptide that has an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- The DNA can be easily obtained by, for example, a general hybridization or PCR method. Specifically, the DNA can be obtained with reference to basic manuals, for example, the above-mentioned Third Edition Molecular Cloning and the like.
- Examples of DNA that contains DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue preferably include genomic DNA, genomic DNA library, cell- or tissue-derived cDNA, cell-or tissue-derived cDNA library, synthetic DNA, and the like. Examples of vectors used for the cloning of genomic DNA fragments into the above-mentioned library include bacteriophages, plasmids, cosmids, phagemids, and the like.
- In the present invention, any RNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue can be used as long as HGF protein can be expressed by reverse transcriptase. Examples of the RNA include RNA obtained by RT-PCR amplification of mRNA fractions harvested from cells or tissues, which is within the scope of the present invention. The RNA also can be obtained by known methods.
- The promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention may contain DNA that encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and that hybridizes under a stringent condition with DNA comprising a base sequence complementary to the DNA encoding HGF partial peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- Such DNA includes DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of the aforementioned DNA encoding HGF partial peptide, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- Examples of such DNA include DNA that encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and hybridizes under a stringent condition with DNA comprising a base sequence complementary to DNA having a partial base sequence of DNA comprising the base sequence represented by SEQ ID NO: 1 or 2.
Specific examples of such DNA include DNA that has a base sequence at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95% homologous to the base sequence of DNA encoding a partial peptide of DNA having the base sequence represented by SEQ ID NO: 1 or 2, and encodes a peptide having an effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. - Herein, "effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue" can be evaluated in the same manner as described above. In addition, hybridization under a stringent condition is the same as defined above.
- "Tendon" can usually be defined as tissue that connects skeletal muscles to bones, and "ligament" can usually be defined as tissue that connects bones to bones. In the present invention, however, "tendon" may include the meaning of a ligament that connects bones to bones. The tendon used in the present invention may include a graft of tendon (hereinafter sometimes referred to as a "tendon graft"), and the ligament used in the present invention may include a graft of ligament (hereinafter sometimes referred to as a "ligament graft").
- Tendon grafts may be tendon autografts or allografts. Typically, tendon autografts to be used may be taken from hamstrings, patellar tendons, or femoral flexor tendons. Tendon allografts generally used are extracted from cadavers, particularly from their hamstrings, patellar tendons, femoral flexor tendons, Achilles tendons, tendons of tibiae or elbows, etc. Synthetic (or artificial) tendon grafts or tendon xenografts may be used. Tendon grafts in which a tendon autograft (or tendon allograft) is hybridized with a synthetic tendon graft etc., may be used. The tendon graft may be multiply folded for use.
- Ligament grafts may be ligament autografts or allograft. Typically, ligament autografts to be used may be extracted from iliotibial tracts etc. Ligament allografts generally used are extracted from cadavers, particularly from their iliotibial tracts, medial collateral ligaments (MCLs), lateral collateral ligaments (LCLs), anterior cruciate ligaments (ACLs), posterior cruciate ligaments (PCLs), outside ligaments, triangular ligaments, tibiofibular ligaments, coracoclavicular ligaments, ligaments of the heads of femora, and the like. Synthetic (or artificial) ligament grafts or ligament xenografts may be used. Ligament grafts in which a ligament autograft (or allograft) is hybridized with a synthetic ligament graft may be used. The ligament graft may be multiply folded for use.
- The "tendon-bone junction" and "ligament-bone junction" are not particularly limited as long as they refer to a region in which a tendon or a ligament is adhered to (fixated or fused with) a bone. Examples thereof include a region where a tendon graft is adhered to the inner surface of a bone tunnel (hole) that is made for securing the tendon graft in ligament reconstructive surgery. The bone tunnel is drilled using, for example, a drill guide, drill, etc.
Examples of ligament reconstructive surgery include ligament reconstructive surgery of the knee joint, ankle joint, elbow joint, wrist joint, shoulder joint, and the like. Specific examples thereof include ACL, PCL, or collateral ligament reconstructive surgery of the knee joint, MPFL reconstructive surgery for recurrent patellar dislocation, lateral ankle ligament reconstructive surgery, ulnar elbow ligament reconstructive surgery, surgery for repairing the rotator cuff of the shoulder joint, and the like. - For example, in ACL reconstructive surgery using a tendon graft, a bone tunnel is established at the upper end (proximal end) of the tibia and the lower end of the femur. After the bone tunnel is drilled, the tendon graft is passed through the bone tunnel and secured so that the graft runs between the tibia and the femur while having substantially the same function as the original ACL. Since the tendon-bone junction tissue is reconstructed at a site where the immobilized tendon graft is in contact with the inner surface of the bone tunnel, or in a space between the tendon graft and the bone tunnel, the tendon graft can serve as a ligament, allowing the recovery of the normal function of the knee joint. Thereby, a ligament is reconstructed between the tibia and the femur.
- Immobilization can be performed using a bone screw (interference fit screw) or a similar fastener, a ligament fastener, suture (for example, nylon thread, silk thread, etc.), etc. A fastener, ligament fastener, and suture can be used alone or in combination. Examples of the ligament fastener include a stainless steel washer (produced by Zimmer K.K.), Endo Button (produced by Smith and Nephew Endoscopy Co., Ltd.), etc.
- The tendon-bone junction or the ligament-bone junction has complicated anatomic features; for example, they include a collagen fiber layer that contains Sharpey-like fibers.
- It is also possible to express "regeneration" as "reconstruction". "Regeneration" indicates that tendon-bone junction tissue or ligament-bone junction tissue is reconstructed. For example, in ligament reconstructive surgery, "regeneration" includes any condition in which the grafted tendon (or grafted ligament) having sufficient strength is adhered to (fixated or fused with) a bone, and physiologically functions in vivo.
Regeneration of the tendon-bone junction tissue or the ligament-bone junction tissue includes the following steps (1) to (5): - (1) a step in which non-directional granulation tissues are formed between the bone and the tendon or ligament graft;
- (2) a step in which collagen fibers are formed between the bone and the tendon or the ligament graft;
- (3) a step in which the collagen fibers are oriented toward the bone;
- (4) a step in which Sharpey-like fibers that enter into bone tissue emerge from the tendon or ligament graft; and
- (5) a step in which the Sharpey-like fibers mature.
- Depending on the type of active ingredient, the promoter for regenerating tendon-bone junction tissue or ligament-bone junction tissue of the present invention can be classified into (a) a promoter comprising HGF protein/partial peptide as an active ingredient, and (b) a promoter comprising a HGF gene as an active ingredient.
- A promoter that comprises as an active ingredient, HGF protein as explained in Item (2) above, partial peptide of HGF protein (HGF partial peptide) as explained in Item (3) above, or a salt of at least one of the HGF protein or partial peptide (hereinbelow sometimes referred to as "HGF protein/partial peptide").
- A promoter comprising as an active ingredient, DNA encoding HGF protein as explained in Item (4) above, (5) DNA hybridizing with the DNA under a stringent condition, DNA encoding HGF partial peptide as explained in Item (6) above, (7) DNA hybridizing with the DNA under a stringent condition (hereinafter, each refereed to as "HGF gene").
- In administering the promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention to a patient, the dosage form, dosing method, dose, etc., may vary when the aforementioned "HGF protein/partial peptide" is used as an active ingredient or the aforementioned "HGF gene" is used as an active ingredient.
- The dosage form, dosing method, dose, etc. , of the promoter of the present invention can be suitably designed or modified depending on the type of active ingredient.
- The promoter (a) can be in any of various dosage forms such as a liquid or solid form. In general, it is preferred that HGF protein, HGF partial peptide, or a salt thereof is formulated in combination with a known carrier into an injection, spray, sustained-release formulation (for example, depot formulation), or the like. The injection or spray may be an aqueous or oily formulation.
- The aqueous injection can be prepared by known methods. For example, an aqueous solvent such as water for injection and purified water, is optionally added a pharmaceutically acceptable additive, such as a tonicity agent (e.g., sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, glucose, and propylene glycol), a buffer solution (e.g., phosphate buffer solution, acetate buffer solution, borate buffer solution, carbonate buffer solution, citrate buffer solution, Tris-buffer solution, glutamic acid buffer solution, and epsilon-aminocaproic acid buffer solution), a preservative (e.g., methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, and borax), a thickener (e.g., hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, and polyethylene glycol), a stabilizer (e.g., sucrose, sodium bisulfite, sodium thiosulfate, sodium edetate, sodium citrate, ascorbic acid, and dibutyl hydroxytoluene), a pH adjuster (e.g., hydrochloric acid, sodium hydroxide, phosphoric acid, and acetic acid) or the like. After HGF protein is dissolved, the solution is sterile-filtered with a filter or the like. The filtered solution is then filled into a sterile container.
- Additionally, an appropriate solubilizing agent, such as an alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, and polyethylene glycol), a nonionic surfactant (e.g., polysorbate 80 and polyoxyethylene 50 hydrogenated castor oil) or the like may also be added. To prepare an oily injection, sesame oil, soy bean oil, or the like may be used as an oily solvent, and benzyl benzoate, benzyl alcohol, or the like may be added as a solubilizing agent. The prepared injection is usually filled into an appropriate ampoule, vial, etc. The amount of the HGF protein in the injection is not limited, but usually can be adjusted to about 0.0002 to 0.5 w/v%, preferably about 0.001 to 0.2 w/v%, based on the total amount of the injection. A liquid formulation such as an injection is preferably freeze-stored, or stored after removing moisture by lyophilization or the like. The lyophilized formulation can be used by adding distilled water for injection or the like as needed and redissolving the formulation.
- A spray also can be prepared by common methods in the formulation practice. To prepare a spray, any additive may be added to the spray as long as the additive is usually used for an inhaled formulation. For example, in addition to a propellant, the above-mentioned solvent, preservative, stabilizer, tonicity agent, pH adjuster, etc., can be added. Examples of the propellant include a liquefied gas propellant or a compressed gas. Examples of the liquefied gas propellant include a fluorohydrocarbon (e.g. alternative freon such as HCFC22, HCFC-123, HCFC-134a, dHCFC142, etc.), liquefied petroleum, dimethyl ether, or the like. Examples of the compressed gas include a soluble gas (e.g., carbon dioxide gas and nitrous oxide gas) and an insoluble gas (e.g., nitrogen gas). The amount of the HGF protein in the spray usually can be adjusted to about 0.0002 to 5 w/v%, preferably about 0.001 to 2 w/v%, based on the total amount of the spray.
- The HGF protein/partial peptide used in the present invention can be formulated into a sustained-release formulation (e.g., a depot formulation) together with a biodegradable polymer. Specifically, a depot formulation of HGF protein/partial peptide can be expected to reduce dose frequency, prolong effects, and reduce side effects. The sustained-release formulation can be prepared by known methods. The biodegradable polymer to be used in the sustained-release formulation can be appropriately selected from known biodegradable polymers, for example, polysaccharides such as starch, dextran, or chitosan; proteins such as collagen or gelatin; polyamino acids such as polyglutamic acid, polylysine, polyleucine, polyalanine, or polymethionine; polyesters such as polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, polycaprolactone, poly-β-hydroxybutyric acid, polymaleic acid, polyanhydride, or fumaric acid-polyethylene glycol-vinylpyrrolidone copolymer; polyortho esters; polyalkyl cyanoacrylates such as polymethyl-α-cyanoacrylate; polycarbonates such as polyethylene carbonate or polypropylene carbonate. Preferable examples include polyester, polylactic acid, and a lactic acid-glycolic acid copolymer; and more preferable examples include polylactic acid and a lactic acid-glycolic acid copolymer. When a lactic acid-glycolic acid copolymer is used, the composition ratio based on the mole percentage (lactic acid/glycolic acid) varies depending on the duration of sustained release. For example, when the duration of sustained release is from about 2 weeks to 3 months, preferably from about 2 weeks to 1 month, the preferable ratio is from about 100/0 to 50/50. In general, the weight-average molecular weight of the polylactic acid or lactic acid-glycolic acid copolymer is preferably from about 5,000 to 20,000. The polylactic acid or lactic acid-glycolic acid copolymer can be prepared by known methods, for example, the method disclosed in Japanese Unexamined Patent Publication No.
S61-28521 - Preferable dosing methods include topical application (direct injection or spray) of an injection or spray to a region (interface) where the bone is in contact with the tendon or ligament graft, or a space between the bone and the tendon or ligament graft, or the surrounding area, and topical application (embedding) of a sustained-release formulation (depot formulation) to the interface or its surrounding area. The dose is appropriately selected according to dosage form, disease progression, age, or the like, and the amount of HGF protein included in the promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention is usually 0.1 µg to 500 mg, preferably 1 µg to 50 mg, more preferably 10 µg to 25 mg per dose. In addition, the dose frequency is also appropriately selected according to dosage form, disease progression, age, or the like. A single dosing or continuous dosing at a certain interval can be selected. The continuous dosing may be performed between once daily and once every several months. For example, dosing with the sustained-release formulation (a depot formulation) or continuous dosing with a sustained-release pump may be performed once every several months.
- The HGF gene is delivered to a patient in compliance with conventional methods, for example, the method described in "Idenshi Chiryo No Kiso-gijyutsu (Basic Technique for Gene Therapy)", a separate volume of Experimental Medicine, Yodosha Co., Ltd., 1996; "Idenshi Dounyu & Hatsugen Kaiseki Jikken-hou (Experimental Method for Gene Delivery and Expression Analysis)", a separate volume of Experimental Medicine, Yodosha Co., Ltd., 1997; and "Idenshi Chiryo Kaihatsu Kenkyu Handbook (Handbook for Research & Development in Gene Therapy)" edited by the Japan Society of Gene Therapy, NTS Inc., 1999; etc.
- Specific examples thereof include topical application (topical injection) of a recombinant expression vector in which the HGF gene is introduced to the interface or its surrounding tissue (for example, bone, muscle, etc.).
- Examples of the expression vector include, but are not limited to, naked plasmids, and DNA or RNA viruses such as detoxified retroviruses, adenoviruses, adeno-associated viruses, herpes viruses (herpes
simplex virus type 1, etc.), vaccinia viruses, poxviruses, polioviruses, sindbis viruses, Sendai viruses, SV40, human immunodeficiency viruses (HIV), etc. Of these, preferable examples include herpes simplex virus type 1 (HSV-1) vectors, Sendai virus envelope (HVJ-E) vectors, adenovirus vectors, adeno-associated virus (AAV) vectors, etc. - A specific HSV-1 vector includes a replication-incompetent HSV-1 (HSV1764/4-/pR19) vector that is severely impaired by the deletion of the three respective genes encoding ICR4, ICP34.5 and VP16 (vmw65), all of which are essential for viral replication (see also Coffin, R.S. et al., J. Gen. Virol. 1998, Vol. 79, pp. 3019-3026; Palmer, J. A. et al., J. Virol., 2000, Vol. 74, pp. 5604-5618; Lilley, C. E. et al. , J. Virol. , 2001, Vol. 75, pp. 4343-4356; etc.). The HVJ-E vector is produced, for example, by the method described in
US Patent No. 6,913,923 . For example, as the HVJ-E vector, GenomONE-Neo EX HVJ Envelope Transfection Kit (produced by Cosmo Bio Co., Ltd.) is preferably used. The AAV vector, which is a non-pathogenic virus, is highly safe and efficient in gene delivery into a cell. Examples of the AAV vector include AAV-2, AAV-4, and AAV-5. Such an HSV-1, HVJ-E, or AAV vector is capable of expressing the target gene in a safe manner for a prolonged period of time. An HSV-1, HVJ-E, or AAV vector capable of safe and prolonged expression is most preferable as a vector used in the present invention. - The form of delivering HGF gene into a patient can be selected from various known forms (for example, an injection, spray, sustained-release formulation (depot formulation), microcapsule, etc.) in response to each of the above-mentioned dosing methods. The injection, spray, and sustained-release formulation (depot formulation) can be prepared in the same manner as described in the section HGF protein. The amount of HGF gene delivery vector varies depending on the type of the HGF gene delivery vector and is not limited. For example, when the formulation is in the form of an injection, the amount of gene delivery vector can be generally adjusted to about 1 x 105 to 1 x 1012 pfu/mL, and preferably about 1 x 106 to 1 x 1011 pfu/mL.
- A microcapsule can be prepared as a fine particle with a diameter of about 1 to 500 µm, preferably about 100 to 400 µm, by coating a core substance, for example, a host cell etc., transfected with the HGF gene-containing expression plasmid, with a coating material in accordance with known methods (for example, a coacervation method, interfacial polycondensation, and a method using a double nozzle). Examples of the coating material include a membranous polymer such as carboxymethyl cellulose, cellulose acetate phthalate, ethyl cellulose, alginic acid and a salt thereof, gelatin, gelatin-gum arabic, nitrocellulose, polyvinyl alcohol, hydroxypropyl cellulose, polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, chitosan-alginate, cellulose sulfate-poly(dimethyldiallyl)ammonium chloride, hydroxyethyl methacrylate-methyl methacrylate, chitosan-carboxymethyl cellulose, alginate-polylysine-alginate, and the like.
- The amount of HGF gene in the formulation and its dose are appropriately adjusted depending on the type of disease intended to be treated, the age and body weight of the patient, etc. The dose can vary depending on the kind of the HGF gene delivery vector. The HGF gene delivery vector is usually administered in an amount of 1 x 106 pfu to 1 x 1012 pfu, preferably 1 x 107 pfu to 2 x 1011 pfu, more preferably 1.5 x 107 pfu to 1.5 x 1011 pfu once every several days to once every several months.
- The promoter of the present invention is suitably applied to humans, as well as other mammals, such as monkeys, cattle, horses, pigs, sheep, dogs, cats, rats, mice, rabbits, hamsters, guinea pigs, chimpanzees, etc.
- As described above, the promoter of the present invention is preferably used at a site (interface) where the bone is in contact with the tendon or ligament graft after surgery, or in the surrounding area. The promoter for the regeneration of tendon-bone junction tissue or ligament-bone junction tissue of the present invention can regenerate tendon-bone junction tissue or ligament-bone junction tissue in the interface or the space between the bone and the tendon or ligament graft.
- The present invention will be described in more detail below by way of examples; however, the scope of the invention is not limited by these examples.
- Method: After intramuscular injection of 3 mg of midazolam (Dormicum; produced by Astellas Pharma Inc.) and 1 mg of medetomidine hydrochloride (Domitor: produced by Nippon Zenyaku Kogyo Co., Ltd.), Japanese white rabbits (2.5 to 3.0 kg) were anesthetized by continuous intravenous injection of about 260 mg/h sodium pentobarbital (somnopentyl; produced by Kyoritsu Seiyaku Corporation). Their hind legs were shaved and disinfected, and each leg was subjected to the following surgery under clean condition. First, an approximately 5 cm incision was made on the skin of the anterior aspect of the hind leg. The extension digitorum longus (hereinbelow, abbreviated as EDL) tendon attached to the lateral femoral condyle was cut at the origin (attachment) of the femur. Subsequently, the lateral surface of the tibia was exposed, and a hole (hereinafter referred to as "bone tunnel") was made from the lateral surface to the internal surface of the proximal tibia, using a drill of 2.5 mm in diameter. As shown in
FIG. 1 , the free end of the EDL tendon (tendon graft) that had been previously cut was pulled into the bone tunnel from the lateral surface of the tibia, then pulled out of the medial surface of the tibia, and secured using a stainless steel washer (produced by Zimmer K.K.) and a 3-0 nylon thread (produced by Bear Medic Corporation). The leg was secured in ankle neutral position. The bone tunnel into which the tendon graft had been pulled was fully washed with physiological saline solution (produced by Otsuka Pharmaceutical Co., Ltd.). Next, cancellous bone containing 10 µL of a mixture obtained by dissolving 10 µg of HGF protein in 10 µL of physiological saline was transplanted to the contact site and space between the bone tunnel and the tendon graft of the right hind leg (HGF administration group). As the HGF protein, HGF protein having the amino acid sequence represented by SEQ ID No. 6 was used. In the contact site and space between the bone tunnel and the tendon graft of the left hind leg, cancellous bone containing 10 µL of physiological saline was transplanted (control group). The cancellous bone collected in the formation of the bone tunnel was used as the cancellous bone (0.05 g). After the transplantation of the cancellous bone, the wound was closed by suture. After the surgery, the rabbits were returned to their cages, and were free to move about without any restriction or immobilization of their extremities. - At 2, 4, 6, 8, and 12 weeks following surgery, nine rabbits each were sacrificed. The tendon graft including the tibia and EDL was taken as a lump of tissue. The distance from the entrance (lateral surface) to the outlet (medial surface) of the hole (bone tunnel) of the proximal tibia was measured using a caliper. Four rabbits were used for histological examination and five rabbits were used for biomechanical testing.
- The extracted tissue was preserved in a 10% (v/v) formalin solution for 2 days, washed with physiological saline, and then immersed in 80% (v/v) methyl alcohol for two days. Subsequently, decalcification was performed using a Plank-Rychlo solution over 7 days. After decalcification, sections were made along the long axis of the bone tunnel of the tibia. The obtained sections were stained with hematoxylin-eosin(HE) and Masson trichrome. The stained sections were observed with an optical microscope and scored using the following criteria.
- Score Criteria
-: The formation of new tissue was not observed in the interface (the contact site and the space between the tendon graft and the bone tunnel). - +: The formation of non-directional granulation tissues was observed in the interface.
++: collagen fibers being oriented toward the bone appeared in the interface.
+++: Sharpey-like fibers appeared between collagen fibers oriented toward the bone in the interface.
++++: The Sharpey-like fibers matured into thick fibers. - Results:
FIG. 2 shows optical micrographs at 8 weeks after surgery. In comparison with the control group (left figure B), the HGF administration group (right figure A) clearly indicates that Sharpey-like fibers and collagen fibers that were oriented toward the bone appeared in the interface. Additionally, the Sharpey-like fibers matured into thick fibers. - Table 1 shows the interface tissue score. Table 1 clearly indicates that, in the HGF administration group, the formation (regeneration) of tendon-bone junction tissue in the interface was promoted at an early postoperative stage.
-
Table 1 Group Score Two weeks after surgery Four weeks after surgery Six weeks after surgery Eight weeks after surgery Twelve weeks after surgery Control + ++ +++ ++++ ++++ HGF Administration ++ +++ ++++ ++++ ++++ - Biomechanical testing was carried out by comparing the rupture strength of tendon-bone junction tissue formed when the tendon graft was attached to the bone tunnel. The ultimate load (Newton: N) per millimeter of the length of the bone tunnel, which was obtained when the tendon graft was pulled out of the bone tunnel, was recorded, and the rupture strength was calculated according to the following formula.
-
The ultimate load is obtained as follows. Using a tensile testing machine (4482 model, produced by Instron Co., Ltd.), the tibia of the extracted tissue was secured to the tensile testing machine, and then the EDL was held and pulled along the long axis of the bone tunnel. The load obtained when the tendon graft was pulled out of the bone tunnel was expressed as the ultimate load. Tendon grafts that had ruptured before being pulled out of the bone tunnel were excluded. - Results: Table 2 shows the rupture strength at 2 and 6 weeks after surgery. At both 2 and 6 weeks after surgery, the rupture strength in the HGF administration group was higher than in the control group.
-
Table 2 Weeks after surgery Group Number Rupture Strength * (N/mm) 2 weeks HGF administration 5 3.59±0.28 Control 5 2.61±0.91 4 weeks HGF administration 5 5.71±0.37 Control 4 4.24±0.43 6 weeks HGF administration 4 6.16±1.17 Control 5 5.27±1.64 8 weeks HGF administration 4 6.72±1.19 Control 4 5.94±1.25 12 weeks HGF administration 3 7.83±1.78 Control 4 6.50±1.55 * Each value indicates average value ± standard deviation - The results reveal that the administration of HGF protein allows for the quick regeneration of strong tendon-bone junction tissue.
- An experiment was conducted in the same manner as in Example 1 except that the HGF protein having the amino acid sequence represented by SEQ ID NO: 4 was used in place of the HGF protein used above.
The results reveal that the HGF protein had the effect of promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue as in Example 1. - Preparation Examples of the promoter of the present invention are described below. In the Preparation Examples, any HGF protein having an amino acid sequence represented by SEQ ID Nos. 3 to 6 can be used as HGF protein.
- A solution in which 1 mg of HGF protein, 1 g of mannitol, and 10 mg of polysolvate 80 were added to 100 mL of physiological saline was aseptically prepared. The solution was placed in a vial in an amount of 1 mL, freeze-dried, and sealed to obtain a promoter in the form of a freeze-dried formulation.
- An aqueous solution in which 1 mg of HGF protein (SEQ ID No. 6) and 100 mg of human serum albumin were added to 100 mL of 0.02 M phosphate buffer solution was aseptically prepared. The aqueous solution was placed in a vial in an amount of 1 mL, freeze-dried, and sealed to obtain a promoter in the form of a freeze-dried formulation.
- 1.9 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50, weight average molecular weight = 10, 000; produced by Wako Pure Chemical Ind. Ltd.) is dissolved in 3.0 mL of dichloromethane. 100 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion. The dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture was stirred and emulsified using a homomixer. Dichloromethane is then vaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. Themixture is then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days. Thereby, sustained release microcapsules containing HGF protein are obtained (the addition ratio of HGF to biodegradable polymer: 5.3 w/w%).
- 1.89 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50, weight average molecular weight = 10, 000; produced by Wako Pure Chemical Ind. Ltd.) and 10 mg of zinc oxide are dissolved in 3.0 mL of dichloromethane. 100 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion. The dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixtureis stirred and emulsified using a homomixer. Dichloromethane is then vaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture was then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days. Thereby, sustained release microcapsules containing HGF protein are obtained (the addition ratio of HGF to biodegradable polymer: 5.3 w/w%).
- 1.7 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 75/25, weight average molecular weight = 15, 000; produced by Wako Pure Chemical Ind. Ltd.) is dissolved in 2.7 mL of dichloromethane. 300 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion. The dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture is stirred and emulsified using a homomixer. Dichloromethane isvaporized by stirring at room temperature for 3 hours, and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules (about 2,000 rpm). Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture is then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days to obtain a sustained release microcapsule containing HGF protein (the addition ratio of HGF to biodegradable polymer: 17.6 w/w%).
- 1.69 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 75/25, weight average molecular weight = 15, 000; produced by Wako Pure Chemical Ind. Ltd.) and 10 mg of zinc oxide are dissolved in 2.7 mL of dichloromethane. 300 mg of freeze-dried HGF protein powder is added to the resulting organic solvent mixture, and pulverized using a mixer mill (produced by Retsch) to prepare a HGF dispersion. The dispersion is added to 800 mL of 0.1 w/v% PVA aqueous solution, and the mixture was stirred and emulsified using a homomixer. Dichloromethane is vaporized by stirring at room temperature for 3 hours and centrifugation (about 2,000 rpm) is performed to separately collect microcapsules. Subsequently, the microcapsules are washed twice using 400 mL of distilled water, and 0.2 g of D-mannitol is added. The mixture was then freeze-dried. To further remove the solvent residue, the resultant is vacuum-dried at 40°C for 3 days to obtain sustained release microcapsules containing HGF protein (the addition ratio of HGF to a biodegradable polymer: 17.8 w/w%).
- 5 g of DL-lactic acid polymer (lactic acid/glycolic acid = 100/0, weight average molecular weight = 5,000; produced by Wako Pure Chemical Ind. Ltd.) is dissolved in 50 mL of methylene chloride to obtain a 10 w/v% solution. Subsequently, 2.5 mg of freeze-dried HGF protein powder is added to the mixture. The resulting mixture is added to a 0. 5 w/v% chitosan aqueous solution that had been separately heated to 40°C, and stirred and emulsified by a homomixer at a stirring rate of 1000 rpm. The emulsion obtained is further stirred for 3 hours at room temperature to evaporate methylene chloride. Subsequently, microspheres obtained by centrifuging (about 2,000 rpm) are collected and washed five times with distilled water that had been heated to 40°C. Subsequently, drying under reduced pressure is carried out at room temperature, and microspheres containing HGF are obtained (the addition ratio of HGF to biodegradable polymer: 0.05 w/w%).
- 10 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 75/25, weight average molecular weight = 5,000; produced by Wako Pure Chemical Ind. Ltd.) is dissolved in 200 mL of a mixture containing methylene chloride and ethanol (4:1) to prepare a 5 w/v% solution. Subsequently, 2.5 mg of freeze-dried HGF protein powder is added to the solution. The mixture is then gradually added to a 1 w/v% gelatin aqueous solution that had been separately heated to 40°C while stirring at a rate of 500 rpm using a homomixer, and emulsified. The emulsion obtained is further stirred for 3 hours at room temperature to evaporate methylene chloride and ethanol. Subsequently, microspheres obtained by centrifuging (about 2,000 rpm) are collected. The collected microspheres are washed five times with distilled water that had been heated to 40°C, and dried under reduced pressure at room temperature to obtain microspheres containing HGF protein (the addition ratio of HGF to biodegradable polymer: 0.025 w/w%).
- 0.2 mL of 2 w/v% HGF-containing aqueous solution and 2 mL of 2 w/v% atelocollagen-containing phosphate buffer solution are mixed and freeze-dried. The HGF-containing aqueous solution can be prepared by the method according to Preparation Example 1. The resulting freeze-dried product is pulverized under low temperature using liquid nitrogen, and then subjected to molding compression using a mold to obtain a cylindrical sustained release formulation containing HGF protein (the addition ratio of HGF to a biodegradable polymer: 10 w/w%).
- 100 mL of 0.01 w/v% HGF-containing aqueous solution and 50 g of 2 w/v% collagen aqueous solution are uniformly mixed while stirring, and freeze-dried. Thereafter, low temperature pulverization is carried out using liquid nitrogen. The resultant is subjected to compression molding to form a rod shape. The sustained release formulation containing HGF protein (addition ratio of HGF to biodegradable polymer: 1 w/w%) was thus obtained.
- 1 mg of HGF protein is dissolved in 2 mL of 2 w/v% atelocollagen solution, and the mixture is freeze-dried. The resulting freeze-dried product is pulverized, and then subjected to compression molding to form a cylindrical shape. The sustained release formulation containing HGF protein is thus obtained (the addition ratio of HGF to biodegradable polymer: 2.5 mass%).
- 0.58 g of sodium salt of hyaluronan (limiting viscosity number: 45, 000 cc/g) and 20 mL of water are mixed and allowed to swell. 2 mL of 2N sodium hydrate is added to the mixture, and stirred to form a homogeneous solution. A solution prepared by adding 0.10 g of divinyl sulfone to 2.4 mL of water while stirring is added to the aforementioned solution to form a mixture. The mixture is allowed to stand for 70 min to obtain a gel. The gel is introduced into 223 mL of BioTris buffer solution (0.15M NaCl phosphate buffer, pH: about 7.2) and allowed to swell for 3 hours. Subsequently, 1 mL of 2N HCl is added to the swollen gel. One hour later, 0.6 mL of 2N HCl is added thereto and allowed to stand for 16 hours. Then, 0.35 mL of 2N HCl is added, and the swollen gel was stirred slowly in the buffer solution for three days to obtain a soft gel with homogeneous viscoelasticity. The gel is dialyzed against 0.15M NaCl for five days. The gel is mixed with 1 w/v% HGF in buffered saline, and the final concentration of HGF protein is set at 0.25 w/v%. The formulation containing HGF is thus obtained (the addition ratio of HGF to biodegradable polymer: about 25 w/v%).
- The promoter for the regeneration of a tendon- or ligament-bone junction tissue of the present invention is useful as a medical drug for promoting the regeneration of a tendon- or ligament-bone junction tissue.
-
-
FIG. 1 shows the EDL tendon of the rabbit ankle joint in Example 1 (left figure), and an embodiment in which the EDL tendon has been transplanted into the bone (right figure). -
FIG. 2 shows the optical microscope photographs of the tendon-bone junction tissue at 8 weeks following EDL tendon transplantation in Example 1. Specifically,FIG. 2A shows the HE-staining image of the HGF administration group andFIG. 2B shows the HE-staining image of the control group. -
- 1. Extension digitorum longus tendon (EDL tendon)
- 5. Bone tunnel
- 10. Stainless steel washer
- 12. Extension digitorum longus (EDL)
- 14. Lateral surface of tibia
- 16. Medial surface of tibia
- 18. Proximal tibia
- 20. Tibia
- 22. Lateral femoral condyle
- 24. Fibula
Claims (10)
- A promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue, comprising the following (1) or (2) as an active ingredient:(1) the following (1-a), (1-b), or (1-c)(1-a) HGF (Hepatocyte Growth Factor) protein,(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(1-c) a salt of (1-a) or (1-b);(2) DNA comprising the following (2-a), (2-b), or (2-c),(2-a) DNA encoding HGF protein,(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- The promoter according to claim 1, wherein the active ingredient is the following (1-a), (1-b), or (1-c):(1-a) HGF protein,(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(1-c) a salt of (1-a) or (1-b).
- The promoter according to claim 1, wherein the HGF protein is the following (1-d) or (1-e):(1-d) a protein having an amino acid sequence represented by SEQ ID NO: 3 or 4,(1-e) a protein having an amino acid sequence at least 85% homologous to the amino acid sequence represented by SEQ ID NO: 3 or 4, and having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
- The promoter according to claim 1, wherein the active ingredient is DNA comprising the following (2-a), (2-b), or (2-c):(2-a) DNA encoding HGF protein,(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- The promoter according to claim 1, wherein the DNA encoding HGF protein is the following (2-d) or (2-e):(2-d) DNA having a base sequence represented by SEQ ID NO: 1 or 2,(2-e) DNA that encodes a protein having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and that hybridizes with DNA having a base sequence complementary to the base sequence represented by SEQ ID NO: 1 or 2 under a stringent condition.
- The promoter according to claim 1, wherein the DNA is inserted into a herpes simplex virus type 1 (HSV-1) vector, a Sendai virus envelope (HVJ-E) vector, an adenovirus vector, or an adeno-associated virus vector.
- The promoter according to claim 1, which is in a form of topical application.
- Use of the following (1) or (2) for manufacturing a promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue:(1) the following (1-a), (1-b), or (1-c),(1-a) HGF protein,(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(1-c) a salt of (1-a) or (1-b),(2) DNA comprising the following (2-a), (2-b), or (2-c),(2-a) DNA encoding HGF protein,(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- The following (1) or (2) for use in a method of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue:(1) the following (1-a), (1-b), or (1-c),(1-a) HGF protein,(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(1-c) a salt of (1-a) or (1-b),(2) DNA comprising the following (2-a), (2-b), or (2-c),(2-a) DNA encoding HGF protein,(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
- A method for promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue comprising: administering the following (1) or (2) to a patient with tendon-bone junction tissue injury or ligament-bone junction tissue injury:(1) the following (1-a), (1-b), or (1-c),(1-a) HGF protein,(1-b) a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(1-c) a salt of (1-a) or (1-b),(2) DNA comprising the following (2-a), (2-b), or (2-c),(2-a) DNA encoding HGF protein,(2-b) DNA encoding a partial peptide of HGF protein, the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue,(2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008068507 | 2008-10-10 | ||
PCT/JP2009/067570 WO2010041716A1 (en) | 2008-10-10 | 2009-10-08 | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2351574A1 true EP2351574A1 (en) | 2011-08-03 |
EP2351574A4 EP2351574A4 (en) | 2012-03-28 |
EP2351574B1 EP2351574B1 (en) | 2016-08-24 |
Family
ID=42100664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09819250.3A Active EP2351574B1 (en) | 2008-10-10 | 2009-10-08 | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue |
Country Status (3)
Country | Link |
---|---|
US (1) | US8927493B2 (en) |
EP (1) | EP2351574B1 (en) |
WO (1) | WO2010041716A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106714823A (en) * | 2014-09-10 | 2017-05-24 | 克霖固鲁制药股份有限公司 | Hgf preparation suitable for treatment of nervous diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066130A1 (en) * | 2000-03-09 | 2001-09-13 | Sulzer Biologics Inc. | Product and method for biological anchoring of connective tissue to bone |
US20030153849A1 (en) * | 1997-02-06 | 2003-08-14 | Huckle James William | Method and apparatus for connective tissue treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0461560B1 (en) | 1990-06-11 | 1998-11-18 | Toshikazu Nakamura | Recombinant human hepatocyte growth factor and method for production thereof |
JP2777678B2 (en) | 1990-06-11 | 1998-07-23 | 敏一 中村 | Recombinant human hepatocyte growth factor and method for producing the same |
JPH05111382A (en) | 1991-10-22 | 1993-05-07 | Saito Signal Kenkyusho:Kk | Human acidocyte cell strain |
JP2903868B2 (en) | 1992-05-14 | 1999-06-14 | 荒川化学工業株式会社 | Printing ink binder |
JP3680114B2 (en) * | 1993-09-17 | 2005-08-10 | 敏一 中村 | Cranial nerve disorder treatment |
JP2980889B2 (en) | 1998-07-09 | 1999-11-22 | 三菱化学株式会社 | Hepatocyte growth factor |
EP1170363B1 (en) | 2000-02-02 | 2007-11-21 | Kaneda, Yasufumi | Virus envelope vector for gene transfer |
US7824701B2 (en) * | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
WO2008105088A1 (en) * | 2007-02-28 | 2008-09-04 | Keio University | Agent for treating spinal cord injury |
-
2009
- 2009-10-08 US US13/123,091 patent/US8927493B2/en active Active
- 2009-10-08 EP EP09819250.3A patent/EP2351574B1/en active Active
- 2009-10-08 WO PCT/JP2009/067570 patent/WO2010041716A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153849A1 (en) * | 1997-02-06 | 2003-08-14 | Huckle James William | Method and apparatus for connective tissue treatment |
WO2001066130A1 (en) * | 2000-03-09 | 2001-09-13 | Sulzer Biologics Inc. | Product and method for biological anchoring of connective tissue to bone |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 200872 Thomson Scientific, London, GB; AN 2008-M32699 XP002669512, & WO 2008/105507 A1 (UNIV KEIO) 4 September 2008 (2008-09-04) * |
JIANG DAPENG ET AL: "Suppression of the production of extracellular matrix and alpha-smooth muscle actin induced by transforming growth factor-beta1 in fibroblasts of the flexor tendon sheath by hepatocyte growth factor", SCANDINAVIAN JOURNAL OF PLASTIC AND RECONTRUCTIVE SURGERY ANDHAND SURGERY, ALMQVIST AND WIKSELL PERIODICAL CO, STOCKHOLM, SE, vol. 42, no. 4, 1 January 2008 (2008-01-01), pages 169-173, XP009156378, ISSN: 0284-4311 * |
SANCHEZ M ET AL: "Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices", AMERICAN JOURNAL OF SPORTS MEDICINE, AMERICAN ORTHOPAEDIC SOCIETY FOR SPORTS MEDICINE, WALTHAM, MA, vol. 35, no. 2, 1 February 2007 (2007-02-01), pages 245-251, XP008100254, ISSN: 0363-5465 * |
See also references of WO2010041716A1 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106714823A (en) * | 2014-09-10 | 2017-05-24 | 克霖固鲁制药股份有限公司 | Hgf preparation suitable for treatment of nervous diseases |
US10213485B2 (en) | 2014-09-10 | 2019-02-26 | Kringle Pharma Inc. | HGF preparation suitable for treatment of neurological disorders |
US10702582B2 (en) | 2014-09-10 | 2020-07-07 | Kringle Pharma Inc. | HGF preparation suitable for treatment of neurological disorders |
Also Published As
Publication number | Publication date |
---|---|
US8927493B2 (en) | 2015-01-06 |
EP2351574B1 (en) | 2016-08-24 |
WO2010041716A1 (en) | 2010-04-15 |
EP2351574A4 (en) | 2012-03-28 |
US20110312887A1 (en) | 2011-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007287510B2 (en) | Treatment of cartilage disorders with FGF-18 | |
JP5607176B2 (en) | Novel peptides and their uses | |
JP5201987B2 (en) | Use of morphogenic proteins to treat cartilage defects | |
DE60123218T2 (en) | PRODUCT FOR BIOLOGICAL BIND WEB ANCHORING OF BONE | |
CA2675953C (en) | Therapeutic agent for spinal cord injuries | |
EP2117578B1 (en) | A peptide composition and a method of promoting cartilage formation | |
CN108697766A (en) | Purposes of the c-type natriuretic peptide variant in treating osteoarthritis | |
JP2006502971A (en) | Connective tissue stimulating peptide | |
DE60133301T2 (en) | TREATMENT PROCESS WITH WISP POLYPEPTIDES | |
HU226201B1 (en) | Cartilage/bone inducing materials for reparation | |
JP2009517387A (en) | How to treat cartilage defects | |
US8927493B2 (en) | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue | |
JP5637854B2 (en) | Regeneration promoter for tendon bone transition tissue or ligament bone transition tissue | |
JP2007238487A (en) | Method for reconstructing neurological function by using hgf for olfactory mucosa graft to spinal cord injury | |
WO2010008023A1 (en) | Bone elongation promoter | |
JP5419045B2 (en) | Spinal cord injury treatment drug | |
RU2813889C2 (en) | Therapeutic agent for cartilage disease | |
WO2024053721A1 (en) | Spinal cord injury therapeutic targeting from acute phase to subacute phase | |
KR100490817B1 (en) | MP-52 Derived Protein Consisting of 119 Amino Acids and Process for Producting the Same | |
JP2997549B2 (en) | Novel protein and its production method | |
KR20050019075A (en) | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110504 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120227 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/22 20060101AFI20120220BHEP Ipc: A61K 38/18 20060101ALI20120220BHEP Ipc: A61P 19/04 20060101ALI20120220BHEP Ipc: A61K 48/00 20060101ALI20120220BHEP Ipc: C07K 14/475 20060101ALI20120220BHEP |
|
17Q | First examination report despatched |
Effective date: 20140929 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602009040662 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0038220000 Ipc: A61K0038180000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 19/04 20060101ALI20160125BHEP Ipc: A61K 38/18 20060101AFI20160125BHEP Ipc: A61K 48/00 20060101ALI20160125BHEP Ipc: C07K 14/475 20060101ALI20160125BHEP |
|
INTG | Intention to grant announced |
Effective date: 20160215 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NAKASE, JUNSUKE Inventor name: TOMITA, KATSURO Inventor name: KITAOKA, KATSUHIKO Inventor name: HANADA, KEIGO Inventor name: MATSUMOTO, KUNIO Inventor name: TSUCHIYA, HIROYUKI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KRINGLE PHARMA, INC. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 822459 Country of ref document: AT Kind code of ref document: T Effective date: 20160915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009040662 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160824 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 822459 Country of ref document: AT Kind code of ref document: T Effective date: 20160824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161124 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161226 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161125 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009040662 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161124 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 |
|
26N | No opposition filed |
Effective date: 20170526 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161008 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091008 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160824 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230914 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230914 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230915 Year of fee payment: 15 |